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ABSTRACT
There is a growing literature for cognitive late effects among childhood cancer survivors,
yet little empirical information is known regarding specific neurocognitive outcomes of children
who experience seizures while treated for acute lymphoblastic leukemia. This study examined
prevalence of on-protocol seizures, seizure risk factors, and neurocognitive change in children
with therapy-related seizures in comparison to the normative sample and a matched cohort of
children without on-protocol seizures. Participants included children enrolled on the St. Jude
frontline leukemia treatment protocol, Total Therapy 15 (TOTXV) - the first systematic
investigation of intensified chemotherapy agents plus optimal intrathecal therapy without
irradiation. Out of 498 children, 19 experienced therapy-related seizures. To increase the
statistical power of comparisons, the 19 children were matched on relevant variables to two
children without on-protocol seizures. Neuropsychological assessment and magnetic resonance
imaging each occurred across three treatment time-points. Results revealed a 3.82% two-year
incidence of seizures during TOTXV with over 50 percent of seizures during induction and
consolidation phases. No demographic or clinical factors were predictive of seizures; although, a
trend for standard/high treatment intensity was observed. When the neuropsychological
performance of the seizure group was compared to normative scores, patterns of differences
emerged and maintained across time-points for domains of attention, working memory, and
processing speed significantly elevated for the seizure group. Similar patterns also emerged
across time-points between the seizure group and the non-seizure cohort. At therapy completion,
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the seizure group performed significantly worse for attention and working memory tasks than the
cohort, and these deficits persisted two years later with the addition of processing speed deficits
and significantly worse intellectual functioning. Imaging findings indicated that children with
therapy-related seizures experienced more significant early neurotoxicity (i.e.,
leukoencephalopathy) than non-seizure cohorts. Based on these preliminary findings, it appears
that children who experience treatment-related seizures are at greater neurocognitive risk when
compared to counterparts who do not. Findings point to a relationship between on-therapy
seizures, leukoencephalopathy, and deficits in neuropsychological performance, specifically
attention, working memory, and processing speed skills, which may lead to overall declines in
intellectual functioning. Further research is needed to identify changes in neurocognitive status
that indicate risk for long-term CNS effect in the hope of providing greater comprehension on
how to earlier treat and prevent cognitive late effects.
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LIST OF ABBREVIATIONS
ALL

Acute Lymphoblastic Leukemia

CNS

Central Nervous System

CRT

Cranial Radiation Therapy

DEX

Dexamethasone

HDMTX

High Dose Methotrexate

ITHMA

Intrathecal Hydrocortisone, Methotrexate, and Ara-C

TOTXV

Total 15 Protocol

MRI

Magnetic Resonance Imaging

DTI

Diffusion Tensor Imaging

AED

Antiepileptic Drug

GABA

Gamma-Aminobutyric-Acid

EIQ

Estimated Intellectual Quotient

FSIQ

Full-Scale Intellectual Quotient

WIAT

Wechsler Individual Achievement Test

FFD

Freedom from Distractibility

DS

Digit Span

PSI

Processing Speed Index

CPT

Conners’ Continuous Performance Test

CPRS

Conners’ Parent Rating Scale
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INTRODUCTION
The American Epilepsy Society (2006) defines a seizure as “the clinical manifestation of
a hyperexcitable neuronal network, in which the electrical balance underlying normal neuronal
activity is pathologically altered—excitation predominates over inhibition.” (p. 6). A diversity of
medical health conditions engenders brain damage and abnormal electroencephalogram (EEG)
activity which predispose patients to seizures. Seizures may also result as a side effect of
treatment and medications. Several medical populations that are susceptible to seizures include
those suffering with encephalitis, meningitis, Huntington’s disease, acquired immunodeficiency
syndrome (AIDS), dementia, multiple sclerosis, stroke, traumatic brain injury, brain tumors, and
other infections of the brain. One particular medical population that is at elevated risk for seizure
experience due to the nature of treatment, and is the focus of this paper, is children treated for
acute lymphoblastic leukemia (ALL).
In order to understand the impact of seizure experience as an indicator of brain damage
within this specific cancer population, it is helpful to first discuss seizure prevalence, etiology,
classification, and clinical management within healthy child populations. It is also useful to
examine the neuropsychological and neuroimaging correlates of seizures within healthy child
populations. Next, this paper considers the neuropsychological consequences that occur within
the context of leukemia treatment, including seizures. Comparisons between healthy children and
children with cancer will aid in parsing out neuropsychological deficits related to leukemia
treatment versus deficits related to seizure experience, with added appreciation for potential
confounding factors or synergistic effects, when changes are observed.
1

Seizures in Healthy Children
Prevalence
Seizures are among the most common, emergent pediatric neurologic problems
(Friedman & Sharieff, 2006; Patel, Walsh, & Garg, n.d.), with approximately three to five
percent of children in the United States experiencing a febrile seizure by age five (Reuter &
Brownstein, 2002) and approximately 4 to 10 percent experiencing a seizure by age 16 (McAbee
& Wark, 2000). Epidemiological research suggests that each year about 150,000 children in the
United States experience a first unprovoked seizure, with 30,000 of those developing epilepsy
(Hauser, 1994).
Developing countries appear to be at two to three times higher risk for first onset seizure
and epilepsy compared to incidence rates of Western, industrialized countries (Banerjee &
Hauser, 2008). A review of studies suggests that males are at higher risk than females for
unprovoked seizures even after controlling for risk factors such as head injury, as well as
individuals from lower socioeconomic levels than those from high socioeconomic status even
after controlling for race (Banerjee & Hauser, 2008). According to the International
Classification of Epileptic Seizures, partial seizures appear the most common seizure type,
accounting for just more than 50 percent of classified cases (Banerjee & Hauser, 2008;
Commission on Classification and Terminology of the International League Against Epilepsy
[ILAE], 1989).
Etiology and Seizure Classification
Seizures have distinctive etiologies and are categorized by particular clinical descriptions
and electroencephalographic wave patterns (Kaufman, 2001). Classification of seizure etiology
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as unprovoked or provoked is important in determining treatment options and prognosis (ChuShore & Tseng, 2011). Causes of provoked seizures include head trauma; central nervous system
(CNS) infections such as meningitis, encephalitis, and subdural empyema; metabolic
abnormalities in glucose, sodium, or calcium levels; and cerebral structural abnormalities such as
congenital malformations, stroke, or mass lesions (Chu-Shore & Tseng, 2011). Prenatal drug
exposure and drug withdrawal must also be considered when identifying possible causes (Reuter
& Brownstein, 2002). The most commonly identified cause of seizures in Western, industrialized
countries is cerebrovascular disease, accounting for 12 percent of new onset cases; whereas, in
South America, the most frequently identified cause is CNS infection (Banerjee & Hauser,
2008).
Classification of seizure type and ruling out epileptogenic syndromes is also informative
for treatment options and prognosis. The most frequently employed taxonomy is the ILAE’s
International Classification of Epileptic Seizures, which was recently reorganized (Berg et al.,
2010). The two major seizure classifications include focal (previously partial), where network
involvement is within just one hemisphere where abnormal activity is discretely localized or
widely distributed, and generalized, where network involvement emerges within and engages
bilateral hemispheres (Berg et al., 2010; Berg & Scheffer, 2011). Within the nomenclature of
focal, it is important to categorize the seizure as either 1) without impairment in consciousness
(simple partial) or 2) with impairment in consciousness, dyscognitive (complex partial). Simple
partial seizures may be further characterized by one or more features: motoric, autonomic, or
sensory/psychic aura aspects. Focal seizures typically last less than two minutes. It is important
to note that focal seizures may evolve into bilateral, convulsive seizures. Generalized seizures
include several categories: tonic-clonic (grand mal), absence (petit mal), tonic, clonic, atonic,
3

and myoclonic. The tonic-clonic seizure typically lasts for three to five minutes. They are often
preceded by an aura, followed by loss of consciousness with skeletal muscle tension (tonic)
causing the person to fall if standing, followed by muscle convulsions that can range from
twitching to violent, rapid movements of the tensed extremities (clonic), with often eyes rolled
back or closed and tongue bruised by jaw contractions. Absence seizures are brief, usually lasting
less than 20 seconds and involve impairment of consciousness with generalized spike-and-slow
wave EEG discharges. Absence seizures are divided into two types: typical and atypical. Typical
absence seizures are clinically identified as staring spells with impaired responsiveness or
awareness and characterized by fast >2.5 Hz generalized spike-wave EEG discharges. Atypical
absence seizures (<2.5 Hz spike and slow wave) may allow some responsiveness and be
accompanied by eye blinking or twitching of the lips. Atonic seizures, or drop attacks, typically
last less than 15 seconds and involve loss of muscle tone, causing the eyelids to suddenly drop as
well as the body to drop if in standing position. Myoclonic seizures are very brief (less than two
seconds) and involve rapid jerking or twitching of a muscle or muscle groups.
Classification is based on a thorough history of clinical symptoms, description of the
seizure event, and the identification of seizure antecedents, such as trauma, fever, or underlying
medical conditions (Reuter & Brownstein, 2002; Williams & Sharp, 2000). While no routine
laboratory procedures exist for first-onset seizures, a physical examination with vitals,
supplemented by blood glucose levels is a good place to start (Reuter & Brownstein, 2002). The
electroencephalogram (EEG) is the preferred laboratory assessment as the presence of abnormal
epileptiform discharges is diagnostic of seizure; however, a normal EEG does not rule out the
possibility of seizures (Williams & Sharp, 2000). Ictal EEG recordings, while ideal, are rare to
capture within the hospital setting and EEG recordings should be scheduled several days to
4

weeks after the first seizure to avoid residual generalized slowing usually seen in the postictal
phase (Reuter & Brownstein, 2002).
Computed tomography or magnetic resonance imaging (CT or MRI) in the acute care
setting is recommended when seizure duration is prolonged beyond 15 minutes, the postictal
phase prevents clinical treatment, or high risk factors would indicate a positive scan of newly
identified neuronal anomalies. Risk factors for positive imaging results include age 6 months or
younger, first-onset focal neurological deficits, and high risk conditions such as a recent CSF
shunt revision, closed head trauma, neurocutaneous disease, and malignancies (Reuter &
Brownstein, 2002).
Clinical Management of Seizures
The gold standard treatment for seizures and epilepsy is antiepileptic drugs or AEDs
(Kaufman, 2001). Given seizures are clinical manifestations of a hyperexcitable neuronal
network, the most successful anticonvulsants combat excitatory neuronal processes and enhance
inhibitory neuronal processes (American Epilepsy Society, 2008). The most important CNS
inhibitory neurotransmitter is gamma-aminobutyric-acid (GABA) and several anticonvulsants
are known to enhance the inhibitory GABA system, such as clonazepam (Klonopin), tiagabine
(Gabatril), pregabalin (Lyrica), and phenobarbital. The most important excitatory
neurotransmitter is glutamate. Glutamate receptor antagonists as novel AEDs are appealing given
their promising prevention of neuronal damage post-stroke and post-status epilepticus in addition
to traditional seizure prevention (American Epilepsy Society, 2008).
Treatments for acute seizures, including status epilepticus, typically include
benzodiazepines (e.g., diazepam, lorazepam, and midazolam), which disrupt and calm the whole
system. Barbiturates (e.g., pentobarbital, phenobarbital, primidone, thiopental) are also
5

commonly used. Both benzodiazepines and barbiturates have direct influence on the important
inhibitory GABA system.
While excessive AED dose concentration generally causes cognitive impairment
including memory and attention difficulties (Kaufman, 2001), there is evidence that typical
administration of anticonvulsants may have deleterious effects on cognitive outcomes.
Management of seizures via AEDs is a matching game of sorts as the individual may be best
treated by an AED other than the one with the best statistical cognitive-behavioral profile in
controlled clinical studies (Devinsky, 1995). Phenytoin has been shown to impair memory and
cognition, which resolves after drug withdrawal (Gallassi et al,, 1988). Two other drug
withdrawal studies of children successfully treated for epilepsy with carbamazepine (CBZ),
phenytoin (PHT), valproate (VPA) monotherapy revealed improved cognitive functioning for
measures of psychomotor speed (Aldenkamp et al., 1993, Blennow et al., 1990). In one study,
children who were seizure-free for a year withdrew from AEDs for three months with
neuropsychological re-evaluation after complete withdrawal at three to four months later.
Improvement was found on just one neuropsychological measure of psychomotor speed, and
children prescribed PHT experienced greater cognitive impairment on measurements of mental
and motor speed than those prescribed CBZ (Aldenkamp et al., 1993). In the other study,
researchers found that withdrawal from AEDs improved performance on binary choice and
visual search tasks, although these findings were similar to the healthy control group (Blennow
et al., 1990). Of mention however is that children prescribed CBZ performed most similar to
healthy children before and after drug withdrawal, whereas children prescribed PHT performed
most poorly. A similar pre- and post-withdrawal poor performance pattern was noted for children
prescribed VPA (Blennow et al., 1990).
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A recent randomized, double-blind, placebo-controlled study examined the impact of
AED discontinuation on measures of attention, reaction time, and information processing speed
in 150 patients without seizures for more than two years on monotherapy AEDs mostly
consisting of CBZ and VPA (Hessen, Lossius, Reinvang, & Gjerstad, 2006). The main finding
was that AED discontinuation significantly improved performance on tasks requiring complex
cognitive processing under time pressure when compared to performance of the nondiscontinuation group. Attention and reaction time tasks were not significantly different between
groups. Similar to Blennow and colleagues’ (1990) findings, when examining drug type,
discontinuation of CBZ produced significant results parallel to the overall study outcome,
whereas VPA discontinuation demonstrated a non-significant trend in the same direction (Hessen
et al., 2006). In a randomized, double-blind study, verbal memory has also been shown to
improve following CBZ and VPA discontinuation (Hessen, Lossius, & Gjerstad, 2011).
Impact of Seizures on Neuropsychological Outcomes
Until the late 90s, research in the area of cognitive outcomes for children diagnosed with
epilepsy focused mostly on overall intellectual functioning and achievement (Williams, Griebel,
& Dykman, 1998). While some researchers asserted that intelligence for children with epilepsy
followed the normal curve seen in the healthy child population, others reported intelligence
findings skewed toward the low average range. Achievement abilities have generally been found
to be disrupted within children diagnosed with epilepsy, regardless of seizure type or treatment.
While some studies point to a hemisphere lateralization of deficits based on seizure type (i.e.,
right versus left temporal lobe epilepsy), others do not evidence hemispheric differences when
examining verbal and performance abilities, personality, or school problems (Camfield et al.,
1984).
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The relationship between seizures and cognitive impairment may be an indirect one,
where learning problems and disruptions in cognitive development are secondary to a general
decreased alertness and inattention stemming from the seizure activity (Sturniolo & Galletti,
1994). Regardless of causal mechanisms, cognitive impairment has been well established in
children with epilepsy (Farwell, Dodrill, & Batzel, 1985; Williams & Sharp, 2000), appearing at
seizure onset (Fastenau et al., 2009) and possibly even emerging before onset based on the
transient cognitive impairment model, in which cognitive disruptions are indicated by
epileptiform EEG discharges (Aldenkamp & Arends, 2004).
Appreciating risk factors and specific causes for neurocognitive deficits is crucial in
prompt intervention for common cognitive and academic difficulties. Given this, there has been a
recent shift from measuring global cognitive abilities to measuring more specific cognitive
abilities. Neuropsychological assessments often include performance measures of memory,
attention, processing speed, language, fine motor skills, executive function, visual motor
integration, and parental report of behavior.
Healthy children with seizures experience adverse effects for specific cognitive
outcomes, including decreased short-term memory, visual spatial difficulties, and poorer
concentration, when compared to same-age peers (Blennow et al., 1990; Dam, 1990). The most
consistent finding across studies in children with seizures is the disruption of attentional skills
(Williams & Sharp, 2000).
Fastenau and colleagues (2009) examined outcomes for four factors of
neuropsychological performance (factor 1: attention/executive/construction; factor 2: language;
factor 3: processing speed; factor 4: verbal memory and learning) and academic achievement for
282 children with first onset seizure in comparison to a healthy sibling group (n=147).
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Neuropsychological deficit was operationalized as 1.3 SD below the healthy sibling norm on the
4 factors, corresponding with the 10th percentile or upper range of borderline intellect. While
there was no difference between groups in academic achievement, children with seizures
performed worse on all measures of neuropsychological functioning when compared to healthy
siblings, particularly for the factor of attention/executive/construction (Fastenau et al., 2009).
Children with seizures also displayed significantly higher odds ratio for neuropsychological
deficits in at least one neuropsychological domain, by important clinical risk factor than the
sibling group (27.4 percent versus 18.2 percent, respectively, χ 2 p = .04), with nearly twice as
many in the seizure group demonstrating deficits for factors of language, verbal memory and
learning, and attention/construction/executive functioning, (13.9 percent versus 7.7 percent for
each factor). The proportion for processing speed was somewhat narrower (13.5 versus 8.4).
Antiepileptic drug (AED) use was related to neuropsychological deficiencies on all four factors.
A second seizure, even in non-medicated children, was found to be related to deficits in
attention/construction/executive functioning. The authors assert that this finding adds to the
conceptualization of deleterious effects of seizures, which are not limited to children with
frequent seizures, generalized symptomatic epilepsy, high AED usage, or extremely early onset
(Fastenau et al., 2009).
Newer research indicates that abnormalities in neuropsychological function, brain
structures, and behavior are present even at, or near, the time of new seizure diagnosis (Hermann
et al., 2012). Thorough clinical histories suggest that neurologic problems and behavioral
difficulties even exist before the first seizure. Within the literature on seizures and epilepsy, the
cause and development of neurobehavioral comorbidities (a broad term which includes cognitive
status, psychiatric status, and social-adaptive behaviors) is covered by Hermann and colleagues
9

(2012) in hope of providing greater knowledge and comprehension on how to treat and prevent
these difficulties.
Three items of evidence are provided by the authors in support of neurodevelopmental
influence of seizures (Hermann et al., 2012). The first piece of evidence includes data revealing
that individuals with earlier age at onset of recurrent seizures suffer more adverse consequences
for cognitive function (Hermann et al., 2002; Kaaden & Helmstaedter, 2009). The second piece
of evidence comes from 30-year-long or longer controlled community and population-based
studies following those with childhood-onset epilepsy, showing that it effects essential quality of
life factors including marriage, employment, income, social involvement, independent living,
psychiatric condition, and other major lifespan outcomes, even in those with intact intelligence
and those in remission without AED assistance (Hermann et al., 2012). Unfavorable lifespan
outcomes have been found to be related to neurobehavioral comorbidities such as early history
of psychiatric or cognitive/learning problems (e.g., Attention-Deficit/Hyperactivity Disorder,
ADHD). The third and final piece of evidence includes population-based and clinical care center
investigations of neurobehavioral comorbidities in children with epilepsy, which indicate
reduced performance in overall cognitive abilities, language abilities, executive function,
academics, mood, nonverbal reasoning, verbal memory, motor functioning, and psychosocial
function (Hermann et al., 2012).
It appears that a number of factors are related to these neuropsychological deficits, such
as age at seizure onset, seizure frequency and recurring seizures, epilepsy type, length of illness,
EEG results, and AED usage. There is some caution, however, in using these variables as sole
predictors given their inconsistency across studies and findings of other factors influencing
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declines in neuropsychological performance, such as pre-existing neuropsychological
impairment, learning difficulties, psychopathology, and family factors (Jones et al., 2010).
Neuroimaging Correlates of Seizures
Although the neuroimaging findings among children with seizures are limited in
comparison to the cognitive impact of seizures literature, it serves as a promising companion to
understanding the neuropsychological consequence and sequelae of seizures. Childhood seizure
onset has been shown to be related to reductions in whole brain volume among individuals with
complicated febrile convulsion (Theodore et al., 2003), abnormal white and gray matter volumes
(Hermann, 2002; Kaaden et al., 2011; Riley et al., 2010), altered volumes of the corpus callosum
(Hermann et al., 2003; Weber et al., 2007), and disruptions in white matter connectivity among
individuals with chronic partial epilepsy (Herman et al., 2003).
Children with Acute Lymphoblastic Leukemia (ALL)
Prevalence of ALL
Leukemia is the most common type of childhood cancer, with acute lymphoblastic
leukemia (ALL) accounting for three out of four cases of childhood leukemia. The American
Cancer Society (2012) estimated approximately 6,050 new cases of ALL in the United States for
2012. For reasons unknown, the incidence of ALL across race is notably higher in Caucasian
children than in African American children, although highest in Hispanic children (National
Cancer Institute, 2012).
Treatment of ALL
Survival rates. Survival rates for children with ALL have improved dramatically over
the past several decades from less than 10 percent to nearly 90 percent (Pui et al., 2009).
Increases in survivorship were initially related to prophylactic treatment of the CNS to reduce
11

secondary malignancies, particularly once-standard cranial irradiation treatment. With the advent
of chemotherapy, prophylactic treatment has improved in its specificity and sensitivity, and in
turn, enhanced survival rates. Although survival has increased, 20 percent of treatment protocols
still employ radiation, with radiation-related cognitive late effects observed in more than twothirds of survivors (Pui, 2004). Cognitive late effects are defined as neurocognitive deficits (e.g.,
executive function, memory, attention, processing speed) and learning difficulties observed at
two to five years after treatment (National Cancer Institute, 2012). Therefore, great efforts have
been made to intensify systemic and intrathecal chemotherapy in order to offset potential risks of
removing cranial irradiation therapy from ALL treatment.
A recent study including more than 21,000 children with ALL (more than half of the
United States’ patients) that took part in the Children’s Oncology Group 1990 to 2005 clinical
trials revealed a higher 5-year survival rate of 90.4 percent for children diagnosed between 2000
and 2005 compared to 83.7 percent for those diagnosed from 1990 to 1994 (Hunger et al., 2012).
Children aged 1 to 9 years are more likely to experience disease-free survival than infants and
children aged 10 or older (Möricke et al., 2005; Schrappe et al., 2000; Smith et al., 1996).
Although prognosis is favorable, childhood cancer survivors are still at risk for
significant acute and long-term sequelae related to disease and treatment, with 60 percent
experiencing at least one long-term treatment-related side effect (Fulbright et al., 2011; Kopp et
al., 2012; Oeffinger & Hudson, 2004). There is increased focus on the effect of chemotherapy on
psychosocial and quality of life issues, including neurobehavioral outcomes (Phipps et al., 2012).
Most often studied indicators of neurotoxicity include global intellectual and academic
performance, although there has been a recent focus on specific neurocognitive processes (Butler
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& Haser, 2006; Phipps et al., 2012). Research data on cognitive late effects of childhood
leukemia support the conceptualization that it is a chronic illness in need of continued care for its
expanding survivorship population (Phipps et al., 2012).
Impact of Chemotherapy Alone on Cognitive Outcomes of ALL Survivors
While the elimination of cranial radiation therapy (CRT) from leukemia treatment has
reduced overall neuropsychological impairment in ALL survivors, neurocognitive problems
(predominately working memory and attention deficits) still exist among the population in subtle
yet significant ways that impact daily life (Ashford et al., 2010; Conklin et al., 2012). Reviews
and meta-analyses of the neurocognitive effects of central nervous system (CNS-directed)
chemotherapy in ALL survivors suggest an adverse impact on several domains of
neuropsychological functioning (Anderson & Kunin-Batson, 2009; Buizer et al., 2005, 2009;
Campbell et al., 2007; Moore, 2004, Nathan et al., 2007; National Cancer Institute, 2012;
Peterson et al., 2008). Cognitive impairments include deficits in intellectual and academic
functioning (particularly arithmetic skills), verbal and nonverbal memory, verbal comprehension,
attention, processing speed, complex fine motor skills, visual-motor integration, visual-spatial
skills, and facets of executive function (Brown et al., 1992; Halsey et al., 2011; Jansen et al.,
2008; Mennes et al., 2005; Moleski, 2000; Peterson et al., 2008). Risk factors that account for
worse cognitive outcomes include younger age at diagnosis, female gender, greater time since
treatment, and higher treatment intensity (Buizer et a., 2005; Buizer et al., 2009; Cohen &
Duffner, 1991; Conklin et al., 2012; National Cancer Institute, 2012; Peterson et al., 2008;
Phipps et al., 2012; von der Weid, 2003).
Leukemia treatment specialists have made a case for refined measurement of cognitive
deficits in particular neuropsychological functions, namely central processing skills, as they
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appear to account for overall intellectual and academic declines, as well as nearly 50 percent of
age-related developmental improvements (Fry & Hale, 1996; Phipps et al., 2012). Central
processing is a mid-level term that includes a subset of performance-based cognitive skills such
as attention to stimuli, speed of processing information, recall of information, and other
executive functions such as working memory, or holding information “online” (Phipps et al.,
2012). Meta-analyses have suggested that ALL survivors experience significant decrements in
these areas (Campbell et al., 2007; Peterson et al., 2008).
Of the central processing skills, deficits in processing speed and working memory skills
appear particularly important in relation to the emergence of cognitive late effects. Of the two,
working memory measurements seem most useful in detecting treatment-related change, as they
are sensitive to cognitive declines even in non-irradiated, chemotherapy-only samples where
treatment intensity is based on risk (e.g., low and standard/high). Increased chemotherapy dosing
of intravenous methotrexate worsens cognitive deficits, specifically declines in attention, (Buizer
et al., 2005) and attentional deficits in ALL survivors have been linked to smaller and abnormal
cerebral white matter volumes (Ashford et al., 2010; Reddick et al., 2006).
Central processing skills as a mediator in cognitive late effects of CNS-directed therapy
is substantiated by the temporal-spatial sequence of neurobehavioral declines in relation to
chemotherapy and temporal-spatial coherence between cognitive declines and decreased cerebral
white matter volumes (Schatz et al., 2000). Ashford and colleagues (2010) also discovered that
working memory performance scores, which identified cognitive deficits overlooked by
estimated intelligence scores, predicted overall intelligence scores. Detecting performance
declines in these specific, purported mediating neuropsychological processes (e.g., working
memory, attention) adversely affected by chemotherapy is necessary to develop targeted, cost14

and time-effective interventions. It will also assist in the discovery and confirmation of neural
pathways hypothesized to be directly related to these neurobehavioral deficits (Phipps et al.,
2012).
Impact of Chemotherapy on Behavioral and Psychological Functioning of ALL Survivors
Surprisingly, children with cancer cope relatively well, often reporting similar or even
lower levels of psychological distress (e.g., depression and anxiety) than healthy peers (Phipps,
2007). Reviews reveal that both self- and other-reports of psychological distress suggest lower
levels of distress in cancer survivors, relative to children with other chronic illnesses (Eiser, Hill,
& Vance, 2000; Lavigne & Faier-Routman, 1992; Noll et al., 1997; Patenaude & Kupst, 2005;
Phipps & Srivastava, 1997).
The lack of maladjustment findings has created skepticism for some researchers who
argue that traditional symptom measures are unable to portray difficulties unique and specific to
the childhood cancer population. As a result, the past decade’s pediatric cancer coping research
has focused on symptomatology of post-traumatic stress disorder (PTSD), particularly
subclinical levels of post-traumatic stress symptoms (PTSS) given null findings of significant
PTSD within the pediatric cancer population (Bruce, 2006). Yet significant differences in PTSS
have not emerged in the few studies comparing pediatric cancer samples to healthy controls
(Barakat et al., 1997; Schwartz & Drotar, 2006).
Research conducted at St. Jude Children’s Research Hospital suggests that adaptive style
plays a more prominent role than history of health condition in contributing to PTSS (Phipps,
Jurbergs, & Long, 2009; Phipps, Larson, Long, & Rai, 2006). Adaptive style, or individual
disposition to perceived threats, was measured by self-reported defensiveness and trait anxiety,
allowing researchers to categorize children’s adaptive style into four groups: repressor, low
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anxiety, high anxiety, and defensive high anxious. Children categorized as low anxious or
repressive adaptive style (low anxiety, high defensiveness) endorsed lower levels of PTSS than
children categorized as high anxious. High anxious adaptive style was associated with a greater
probability of arousal, avoidance, numbing, intrusive thoughts, and re-experiencing of events
(Phipps et al., 2006). In a following study with an added healthy child control group, the adaptive
style findings were replicated regardless of health condition and there was a lack of significant
group differences for PTSS (Phipps et al., 2009). Relapse was the only cancer-related variable
correlated with elevated PTSS. While children with cancer endorsed greater numbing and
avoidance than healthy children, they also endorsed fewer intrusive thoughts and trauma reexperience. Other research findings and reviews have also questioned the conceptualization of
childhood cancer experience as a traumatic event, offering alternative conceptual models such as
“psychosocial transition” (Cordova & Andrykowski, 2003; Deimling et al., 2002) and “posttraumatic growth” (Barakat, Alderfer, & Kazak, 2006).
Impact of Chemotherapy on Neuroimaging Outcomes
While CRT with and without chemotherapy (primarily methotrexate) has been strongly
linked to intracranial white matter changes, vascular damage, and other serious
neuropsychological and neuroendocrine issues (Cohen & Duffner, 1991; Packer et al., 1987),
chemotherapy alone has also been considered by some investigators to result in comparable
neurocognitive side effects (Buizer et al., 2009). Consequences of chemotherapeutic drugs
include brain atrophy, vascular injury, and white matter damage; the latter termed
leukoencephalopathy or reversible acute methotrexate neurotoxicity (Anderson & Kunin-Batson,
2009; Paakko et al., 2000; Reddick et al., 2006; Wilson et al., 1991). Leukoencephalopathy
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prevalence, measured by MRI, is as high as 86 percent after seven intravenous high-dose
methotrexate (MTX) rounds, with a reduced 40 percent at treatment completion (Reddick et al,
2005). If methotrexate neurotoxicity has not reversed at end of therapy, it is thought to resolve
within a year or so after (Haykin et al., 2006; Wilson et al., 1991; Ziereisen et al., 2006).
However, using single-photon emission computed tomography (SPECT), Paakko and colleagues
(2000) discovered small brain perfusion defects at up to eight years post-treatment, which were
missed by perfusion MRI.
Younger aged children’s developing brains are more vulnerable to therapy-related
neurotoxicity, evidenced by measured decreased cerebral white matter volumes and increased
oxidative stress in the CNS post-treatment (Rajamani et al., 2000). Females appear to be
particularly vulnerable to the effects of CNS-directed therapy as males’ neurodevelopmental
experience involves greater white matter volume increases in childhood (Maytal et al., 1995).
Biomarkers of oxidative stress include increased levels of brain specific proteins. Oxidized
fractions of the most prevalent cerebrospinal fluid phospholipid called phosphatidylcholine (PC)
measured after induction and consolidation phases of chemotherapy treatment predict executive
function decline two years later (Caron et al., 2009).
Impact of therapy medications. Leukemia chemotherapeutic agents commonly include
methotrexate (MTX), cytosine arabinoside (Ara-C), L-asparaginase (L-ASP), and vincristine
(VCR). Experts have hypothesized how these agents contribute to cognitive late effects, with
more recent investigation on MTX. Methotrexate interferes with folate metabolism by inhibiting
the enzyme dihydrofolate reductase (DHFR) from converting dihydrofolates into active folate.
Folate deficiency results in elevated levels of homocysteine, causing vascular endothelial injury
and allowing permeability of the blood brain barrier to chemotherapeutic agents. With more
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agents in the central nervous system, homocysteine excitotoxicity and neuronal death occurs,
which may clinically present as focal neurological deficits, stroke-like episodes, and/or seizures
(Anderson & Kunin-Batson, 2009; Rao et al., 2002). Excess homocysteine may also enhance
levels of glutamate, which is found in epileptogenic foci, resulting in calcium influx that
similarly causes excitotoxicity and neuronal death. In general, acute MTX neurotoxicity is
associated with calcification, hemorrhage, thrombosis, or white matter signal abnormalities (Rao
et al., 2002).
Disruptions in the folate and homocysteine systems link to physiological changes in the
brain as well as neurocognitive late effects. Active MTX therapy has been associated with
abnormal frontal lobe white matter and working memory deficits at end of treatment, yet the
long-term effects related to these changes are not clear (Ashford et al., 2010; Khong et al., 2006;
Reddick et al., 2005a). Smaller white matter tissue volumes have also been significantly
associated with greater decrements in intelligence, academics, and attention (Reddick et al.,
2006). Reduced frontal lobe white matter volumes in childhood cancer survivors, when
compared to healthy controls, have been linked with deficits in attention, mathematics, mental
flexibility, and visual-construction abilities (Carey et al., 2008). Imaging studies employing
computed tomography (CT) and magnetic resonance imaging (MRI) have revealed calcifications
at neural pathways that involve intellectual, memory, and attentional abilities (i.e., basal ganglia
and gray-white matter junctions).
Glucocorticoids, such as dexamethasone and prednisone, are also a part of leukemia
treatment. While they demonstrate helpful anti-inflammatory and immunosuppressant functions,
they also initiate metabolic changes, which may result in seizure experience. Glutamate
excitotoxicity, particularly occurring in the hippocampus, results in neuronal death (Hoschl &
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Hajek, 2001), which also is a potential initiating factor of seizure episodes. Dexamethasone,
which has a longer half-life than prednisone and other corticosteroids plus more readily
infiltrates the CNS, is of particular concern when considering the neurocognitive development of
children undergoing ALL treatment (Bostron et al., 2003; Phipps et al., 2012). Children treated
with dexamethasone demonstrated a lower mean IQ of 11 points and poorer performance on
measures of academic achievement and visual-spatial skills as compared to children treated with
prednisone (Waber et al., 2000).
Seizure Occurrence among Children Treated for ALL
Prevalence of Seizures during Leukemia Treatment
Among the neurological complications seen in leukemia therapy, seizures are one of
many (e.g., transient ischemic attacks, meningitis, polyneuropathy, transient paresis or paraplegic
attacks, transient dysarthria, ataxia, aphasic episodes, acute altered mental states such as
disorientation, loss of consciousness, and irritability, and postintrathecal severe headaches).
Children with ALL are a specific pediatric cancer population with unique risk factors for and
pathophysiologic causes of seizure development, such as toxic-metabolic disturbances (Antunes,
2003). Within the childhood cancer literature, approximately 3 to 13 percent of children treated
for acute lymphoblastic leukemia (ALL) experience seizures (Fasano & Bergen, 2009; Goldsby
et al., 2010; Kuskonmaz et al., 2006; Mainero et al., 2000; Maytal et al., 1995; Ochs et al., 1984;
Skoczen et al., 2004).
Associated Risk Factors for Seizures
Data from a Memorial Sloan-Kettering Cancer Center pediatric oncology database
revealed that out of 384 children diagnosed with systemic cancer, 47 were positive for seizures
(Atunes, 2003). Out of the 47 children with underlying cancer and seizures, 22 (46.8 percent)
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children were diagnosed with leukemia, and more specifically 16 (34 percent) children with
ALL. From the sample of 47 children, the age distribution indicated a risk for younger children
(aged ≤ 10). The sex distribution indicated a slightly higher occurrence of seizures in males (n =
27), particularly those diagnosed with ALL (Atunes, 2003). This is contrary to the finding by
Maytal and colleagues (1995) from a sample of 127 children treated for ALL that revealed girls
at higher risk for seizures than boys. Higher doses of intrathecal and intravenous MTX have been
previously linked to seizure experience (Ochs et al., 1984).
Seizure Onset, Type, and Duration
When treatment-related seizures occur, the onset often takes place during the first six
weeks of acute induction and consolidation (Fasano & Bergen, 2009). A majority of seizures
occur between weeks three and four of the induction phase (Gerrard, Eden, & Lilleyman, 1986).
Consistent with those temporal findings of seizure occurrence in earlier phases of leukemia
treatment, a study of 1,395 pediatric patients undergoing therapy for ALL who received triple
intrathecal therapy with or without high-dose MTX revealed that one percent (15 patients)
experienced seizures: six during induction, four during consolidation, one during interphase, two
during intensification, and two during maintenance therapy (Dufourg et al., 2010). In a
retrospective study of adult survivors of childhood ALL, roughly 6 percent (249 out of 3,860
patients) reported a seizure disorder and over half of those were classified as late-onset: 5 years
post-diagnosis (Goldsby et al., 2010).
Regarding seizure type, Ochs and colleagues (1984) observed a majority of seizures
(93/96) to be primary generalized tonic-clonic (grand mal) or focal motor seizures, with severity
of seizure classified as status epilepticus for 38 and recurrent for 45. However, these numbers on
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seizure type and duration may be reflective of the older, less-refined methods of CNS
prophylaxis, including high-doses of intrathecal MTX combined with cranial irradiation.
Pathophysiologic Etiology of Seizures
Among children treated for ALL, Rao and colleagues (2002, p. 1335) noted that the most
common etiologies of seizures include “metabolic disturbances, coagulopathy with cerebral
infarction or venous sinus thrombosis, intracerebral hemorrhage, CNS infection, fever,
meningeal leukemia and drugs (such as MTX and L-asparaginase).” Kuskonmaz and colleagues
(2006) noted cerebral thrombosis and ischemic infarction to be the most common etiologies,
accounting for 40 percent of seizure presentations. The sample included 20 children treated for
ALL that were reported to have neurological complications, with 10 of them experiencing
seizures. One possible culprit of intracerebral hemorrhage and thrombosis identified was the
chemotherapeutic drug, L-asparaginase (L-ASP). The mechanism of action behind L-ASP is
believed to be declines in proteins that are necessary for proper coagulation and fibrinolysis
(Kuskonmaz et al., 2006).
Among a sample of children with leukemia, in addition to metabolic factors, arterial
hypertension and leukoencephalopathy were observed as common causes of seizures, with
leukoencephalopathy believed to be the most common etiology (Antunes, 2003). Other
researchers have observed this same relationship between leukoencephalopathy and treatmentrelated seizures. Abnormal structural brain changes were secondary to vascular-related injuries
of leukemia treatment involving high-dose intravenous and intrathecal chemotherapy,
specifically white matter damage secondary to methotrexate (Lövblad et al., 1998).
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Treatment for Seizures and Prognosis
It is recommended that children with ALL who experience a first seizure during an early
treatment phase should undergo brain imaging and coagulation studies (Maytal et al., 1995). If
tests show no clear etiology, a complete metabolic work-up and cerebral spinal fluid (CSF)
evaluation is advised to rule out electrolyte imbalance, disease relapse, and infection. Children
with ALL who have an acute symptomatic seizure without any neuroatypicality or brain lesions
should be observed closely without AEDs after correction or elimination of etiology of seizure. If
neuroatypical results are found or seizures reoccur, AEDs are suggested for one to two years or
until leukemia treatment is complete. However, long-term AEDs are cautioned (Relling et al.,
2000). Treatment modifications may also be appropriate. Reduced dosing or discontinuation of
chemotherapeutic drugs, such as vincristine, L-asparaginase, or intrathecal MTX, is advised
(Gerrard et al., 1986). In leukemia treatment protocols with CRT, when feasible, delaying cranial
irradiation for one to seven months or omitting cranial prophylaxis altogether has been proposed.
Regarding the prognosis of those who experience treatment-related seizures, Maytal and
colleagues (1995) reported that 35 percent (6 out of 17 patients) had recurrent seizures, with 28
percent developing epilepsy (2 out of 17 patients). Dimario and Packer (1990) reported that 13
percent of their sample (4 of 30 patients) developed epilepsy. In a larger sample of 203 ALL
patients, Kuskonmaz and colleagues (2006) found that while 5 percent (10 out of 203)
experienced seizures and 2.5 percent (5 out of 203) developed epilepsy, there was a 50 percent
risk of developing epilepsy after the first seizure (5 out of 10 patients). Out of the 20 patients
with neurological complications, 25 percent (5 patients) developed epilepsy.
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Cognitive Outcomes Data is Limited
While the rate of therapy-related seizures among children treated for leukemia is
established, the cognitive impact of seizures is not well known in this population. Among
children with CNS relapse, Mulhern and colleagues (1987) found weak negative correlations
between seizures and overall cognitive and academic functioning. However, a significant
moderate negative correlation was found between seizures and performance IQ (r = -0.42, p <
.01). Rao and colleagues (2002) noted that patients experiencing seizures are “at a higher risk for
… recurrent seizures and delayed intellectual development” (p. 1335). However, little is known
about the cognitive outcomes and neuropsychological status of ALL survivors that experienced
treatment-related seizures.
Behavioral and Psychological Functioning Data is Limited
The data for behavioral and psychosocial outcomes of children who experience seizures
while treated for leukemia is also limited. Fasano & Bergen (2009) followed five adults in their
mid-late twenties (range = 25-29) who had been diagnosed with ALL before the age seven and
later developed intractable epilepsy (defined as at least 1 seizure per month), years after ALL
treatment completion. It is important to note that all five were treated with whole-brain
irradiation and chemotherapy. Mean years for seizure experience post-treatment was 7.5 years,
with mean age of seizure experience at age 10.
Findings indicated that three of the five experienced first seizure during treatment and all
five were treated with multiple AEDs (Fasano & Bergen, 2009). While three responded to AEDs
for several years, seizures returned. Only two, who experienced seizure onset during middle
adolescence, completed high school. All five were cognitively impaired, with one unable to
maintain employment, one living at home with parents, and two placed in care facilities. The
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specific living circumstances of the other two were not reported; however, they were classified
as borderline intellectual functioning and verbally impaired.
Neuroimaging Outcomes Data is Limited
While there is imaging data for children who were treated for leukemia, the data for
imaging outcomes of children treated for ALL who experience seizures is limited. Rao and
colleagues (2002) investigated the case of a 27-year-old woman with tonic-clonic seizures who
was treated with active MTX. MRI revealed enhancement in the meningeal, cortical, and
subcortical brain regions, as well as focal white matter hyposignal and cerebrospinal fluid (CSF)
infiltration. CT scan revealed white matter signal abnormalities, thrombosis, ischemic stroke, and
bilateral parietal hypodensities. CSF exam revealed a slight increase in protein, for which she
was treated with phenytoin for three months. A follow-up MRI at 10 days later revealed
resolution in aforementioned enhancements. In this specific case, the pattern of brain damage
(calcification, hemorrhage, thrombosis, and white matter abnormalities) was classified as acute
MTX neurotoxicity (Rao et al., 2002).
Another CT and MRI study examined neuroimaging findings of four children with ALL
hospitalized for seizures after treated with high-dose intravenous and intrathecal chemotherapy
(Lövblad et al., 1998). In all four children, CT was positive for diffuse periventricular white
matter hypodensities and in three of the four children, subcortical hyperdense foci were present.
In all four cases, MRI revealed diffuse hyper-intense white matter lesions on T2-weighted
images, which was concordantly observed on susceptibility-sensitive FLASH sequences in the
CT hyperdense foci as well as T1-weight images of hyperintense foci. Therefore, the authors
asserted that the white matter lesions with calcification were related to leukoencephalopathy,
namely a pure form of methotrexate encephalopathy, resulting in seizures (Lövblad et al., 1998).
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CURRENT STUDY
Purpose of this Study
While the literature reports on the prevalence, onset, prognosis, and treatment of seizures
during leukemia treatment, and while there is a whole host of data on cognitive outcomes for
childhood cancer survivors indicating cognitive late effects, little empirical information is
available regarding specific cognitive outcomes for children treated for ALL who experience
therapy-related seizures. We desired this information given the importance of identifying
cognitive risk early in treatment with respect to treatment planning, monitoring, and caregiver
education. To address this gap in the literature, this study examined the relationship between
seizures during leukemia therapy and cognitive outcomes in childhood leukemia survivors in the
hope that it improves these aspects of care.
Current Study Objectives and Hypotheses
Our first study objective was to estimate the rate of seizure occurrence in children treated
for ALL and identify demographic and clinical factors associated with seizure risk, such as age at
diagnosis, gender, race, treatment intensity, and prior history of seizures. We also examined
which treatment phases had the highest frequency of seizures. Given the removal of cranial
irradiation and overall reduction of therapy intensity in the current study protocol, we estimated
that the rate of seizure occurrence in the current sample was within the low range seen in the
literature, roughly three to five percent. We predicted that clinical factors of prior history of
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seizures and therapy intensity would be associated with seizure risk during leukemia therapy,
with a greater number of seizures occurring during induction and consolidation phases.
Our second study objective was to assess neurocognitive change in children with therapyrelated seizures by comparing their performance on neuropsychological measures across time
points of first assessment, end of therapy, and two years post therapy completion. We predicted
that children who experienced treatment-related seizures would significantly worsen in cognitive
performance from first assessment to two years post therapy completion.
Our third study objective was to compare the neuropsychological performance of
children who experienced therapy-related seizures to the normative sample as well as to the
performance of a cohort of similarly treated patients without seizures matched on relevant
variables (i.e., gender, age at treatment, risk arm). We predicted that post-treatment cognitive
performance among children with treatment-related seizures would be significantly worse
compared to the normative sample as well as the performance of the matched cohort of similarly
treated patients without seizures.
Our fourth study objective was to compare the rate of leukoencephalopathy (i.e., white
matter damage) between children who experienced therapy-related seizures and the matched
cohort of similarly treated patients without seizures. We predicted a significantly greater
occurrence of leukoencephalopathy among children with treatment-related seizures compared to
similarly treated patients without seizures.
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METHODOLOGY
Participants
Participants (N = 498) included children enrolled on the St. Jude frontline leukemia
treatment protocol, Total Therapy 15 (TOTXV), which was the first systematic investigation of
intensified chemotherapy agents plus optimal intrathecal therapy, without any prophylactic
cranial irradiation (Pui et al., 2009). Out of the 498 children on protocol, 19 experienced therapyrelated seizures. Out of those 19 children, two children had a prior history of seizures. To
increase the statistical power of comparisons, each of the 19 children who experienced ontherapy seizures were matched to two similarly treated children on protocol without seizure
experience (n= 38). Matching variables included gender, race, age at treatment, and treatment
intensity.
Measures
Measurements included three time points for neuropsychological assessment as well as
imaging. Neuropsychological testing was conducted at first assessment (week 6 continuation),
end of therapy (week 120 continuation), and two years post therapy completion. Imaging was
conducted at the end of 6-week remission induction, week 7 continuation, and end of therapy
(week 120 continuation).
Neuropsychological assessment. Neuropsychological measurements included
performance-based assessments of overall intellectual functioning, academic achievement,
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attention and working memory, as well as parental report of behavioral problems. The
assessment battery has been previously described in detail (Conklin et al., 2012).
Intellectual functioning. Overall cognitive functioning was measured using ageappropriate intelligence tests, including the Wechsler Adult Intelligence Scale – Third Edition
(WAIS-III; Wechsler, 1997; ages > 16), Wechsler Intelligence Scale for Children – Third Edition
(WISC-III; Wechsler, 1991; ages 6-16), Wechsler Preschool and Primary Scale of Intelligence –
Revised (WPPSI-R; Wechsler, 1989; ages 3-6), and Bayley Scales of Infant Development –
Second Edition, Mental Development Index (BSID-II MDI; Bayley, 1993; ages 1-3). All
Wechsler scores and the BSID-II MDI have an age standardized mean of 100 and standard
deviation of 15. Estimated Intelligence Quotient (EIQ) scores were obtained at all three
assessment time-points; whereas Full Scale Intelligence Quotient (FSIQ) scores were obtained at
the second (end of therapy) and third (two years post therapy completion) assessment timepoints. EIQ was calculated from the Information, Similarities, and Block Design subtests from
the WAIS-III, WISC-III, or WPPSI-R using a formula provided in Sattler (1992), which
correlates highly with FSIQs (r = .93).
Academic Achievement. Academic achievement was assessed using two subtests from
the Wechsler Individual Achievement Test (WIAT; Wechsler, 1992): Word Reading and Math
Reasoning. The WIAT is similar to the other Wechsler (IQ) tests in that it employs age-based

scores, with a mean of 100 and standard deviation of 15, and was standardized using the same
sample as the WISC-III. Internal consistency reliabilities for the two subtests are adequate,
within the high .80s to mid .90s (Wechsler, 1992). Criterion-related validity is adequate as
moderately high correlations (rs = .70s to .80s) have been observed between the WIAT and
previously established individually administered achievement tests, such as the Woodcock28

Johnson Psycho-Educational Battery-Revised, Tests of Achievement (rs = .68 to .88), the Wide
Range Achievement Test-Revised (rs = .69 to .87), the Kaufman Test of Educational
Achievement (rs = .73 to .87), and the Peabody Picture Vocabulary Test-Revised (rs = .68 to
.75). Test-retest reliabilities from a sample of 367 students across five grades ranged from the
mid .80s to low .90s (Wechsler, 1992).
Attention, working memory, and processing speed. Participants between the ages of 6
and 16 were administered the WISC-III, which allowed Wechsler indices of attention, working
memory, and processing speed to be examined. Indices include Freedom from Distractibility
(FFD), Digit Span Total (DS), and Processing Speed Index (PSI), respectively. The Conners’
Continuous Performance Test (CPT; Conners, 2000a), a computerized measure of selective and
sustained attention, was also administered to participants aged 6 and older. During the 14-minute
task, children are instructed to press the space bar as quickly and accurately as possible for letters
(targets presented at 250ms each), except ‘‘X’’ (non-target, which appears on 10 percent of the
360 trials). Intervals between stimuli vary by lengths of 1, 2, or 4 seconds depending on the trial
block. The CPT computes multiple indices and of interest to the current study are indices
suggesting inattention or failure to respond to a target (Omission Errors) and processing speed
(Reaction Time). Index scores are age standardized, with a percentile score calculated for
Omission Errors (mean of 84, standard deviation of 6) and a T-score calculated for Reaction
Time (mean of 50, standard deviation of 10). Test-retest reliabilities range from .55 to .84 for a
3-month interval (Conners, 2000a). Construct-related validity is evidenced by differences in
performance between children with ADHD diagnoses and those without (Seidel & Joschko,
1990). The CPT has insignificant practice effects for repeat administration, with reliable
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classification of children with inattention at roughly 87 percent sensitivity and 74 percent
specificity (Conners, 1995).
Parent report of behavioral problems and attention abilities. Behavioral problems and
inattention symptoms were assessed using four subscales of the Conners’ Parent Rating Scale
(CPRS, Conners 2000b): Learning, Psychosomatic, Impulsive-Hyperactive, and Hyperactive.
CPRS subscales are age and gender standardized, with a T-score (mean of 50, standard deviation
of 10). Internal consistency reliabilities range from the mid .80s to mid .90s, with adequate testretest reliability. Criterion-related validity is evidenced by significant correlations with the
Conners’ CPT (r = .44; Conners, 1995).
Leukoencephalopathy assessment. MRI exams were classified categorically as either 1)
normal appearing white matter or 2) leukoencephalopathy/white matter damage by
neuroradiologist, Dr. Fred Laningham, who was blind to neuropsychological assessment. The
imaging protocol has been previously described in detail (Ashford et al., 2010). Images were
acquired using a 1.5 Tesla Avanto whole-body MRI scanner with a standard circularly polarized
volume head coil (Siemens Medical Systems, Iselin, NJ). Leukoencephalopathy, or
hyperintensities within white matter, is best imaged with a T-2 weighted sequence preferably
with attenuated cerebrospinal fluid.
The current protocol quantified images using an automated hybrid neural network
segmentation and classification method (Reddick, Glass, Cook, Elkin, & Deaton, 1997). Image
sets included most of the cerebrum, beginning at the apex of the brain, excluding the cerebellum.
Imaging was obtained using at minimum 19 oblique 4-mm-thick axial images with 1-mm gap. T2 weighted images were acquired using a dual spin-echo sequence (TR/TE1/TE2 =
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3500/17/102ms, 7 echoes). Fluid-attenuated inversion recovery images were acquired with a
multi-echo inversion recovery sequence (TR/TE/TI = 9000/119/2470 ms; 11 echoes).
Procedure
Relevant data was extracted from the TOTXV database as well as through retrospective
review of medical records for children treated on the TOTXV protocol.
Data Analytic Strategy
Prior to analyses, all values were examined to ensure accuracy of data entry. All data
were screened to detect values outside the range of possibility. Mahalanobis distance detected no
extreme outliers for exclusion from analyses. An alpha level of .05 was used to assess the
significance of all statistical comparisons. To characterize the sample, qualitative analyses of
demographic and clinical variables were performed. Demographic and clinical variables were
also examined to ensure group equivalence. Cumulative incidence was utilized to estimate the
rate of seizure occurrence in children treated on TOTXV and identify demographic or clinical
factors associated with seizure risk. For the following analyses, P values were not adjusted for
multiple comparisons as it will result in fewer errors of interpretation given that the current data
being examined are not random numbers but rather actual observations on nature (Rothman,
1990). One-way repeated measures ANOVA was utilized to assess change in the
neuropsychological performance of children with therapy-related seizures across three
assessment time points. One-sample t-tests were utilized to compare the neuropsychological
performance of children with therapy-related seizures at each time point to published normative
scores. Mixed Model repeated measures ANOVA was utilized to compare the
neuropsychological performance of children with therapy-related seizures to the
neuropsychological performance of a matched non-seizure cohort across time points. Fisher’s
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exact test was utilized to compare the rates of leukoencephalopathy classification at each
neuroimaging time point between children with therapy-related seizures and the matched nonseizure cohort.
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RESULTS
Group Equivalence for Age, Race, Gender, and Treatment Intensity
Descriptive statistics of relevant demographic and clinical variables (i.e., age, race,
gender, and treatment intensity) were derived to ensure group equivalence on these matched
variables. Table 1 displays the mean, median, and range of ages for each group at diagnosis.
Ages ranged from 2 to 18 years old, with a mean age of 8.2 across groups. A one-way betweengroups analysis of variance revealed no statistically significant differences for age across the
three groups (p = .99). Table 2 displays the remaining relevant variables (i.e., race, gender, and
treatment intensity). Using Pearson’s Chi-Square Test, no significant differences between the
seizure and non-seizure cohort groups existed at diagnosis for race, gender, and treatment
intensity (p = .68; p = .99; p = .99, respectively, Table 2).
Sample Incidence Rate of Seizures and Associated Factors
To address the first study objective, the cumulative incidence of children who
experienced seizures during TOTXV therapy was calculated relative to the entire TOTXV
sample. Grade 3 seizures were defined as altered consciousness. The estimated 1-year and 2-year
cumulative incidence rates of Grade 3 and higher seizures were 3.21% ± 0.79% and 3.82% ±
0.86%, respectively (Figure 1).
Cumulative incidence curve and estimates were also utilized to identify whether any of
the selected demographic and clinical variables were statistically associated with risk for ontherapy seizures. The cumulative incidence of seizure (i.e., first event) was tested between
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groups by using the method described by Gray (1988) and the estimation was produced by using
the method described by Kalbfleisch and Prentice (1980). None of the relevant factors of age at
diagnosis, race, or gender had a statistically significant effect on seizure development (p = .15; p
= .33; p = .27, respectively, Table 3). Treatment intensity was trending toward statistical
significance, with Standard/High Risk group having a higher estimated rate than the Low Risk
group at 2-year cumulative incidence (5.6 ± 1.6 versus 2.5 ± 0.9, respectively, p = .06, Table 3).
There were no significantly different dosings (mg/m2) of therapeutic agents, which included
dexamethasone (DEX, p = .96), high dose methotrexate (HDMTX, p = .25), and intrathecal
therapy (ITHMA: hydrocortisone, methotrexate, and cytarabine/Ara-C, p = .45), between
children who experienced therapy-related seizures and children who did not (Table 4).
A frequency count of seizure onset during each treatment phase was calculated and totals
were transformed into percentages of seizure occurrence by phase (Table 5). The Induction and
Consolidation phases were the two most prominent phases for Grade 3 seizures to occur, each
accounting for approximately 26 percent of seizures. Fifty-two percent of seizures occurred
during these early phases of treatment.
Cognitive Outcomes Comparisons
For the second objective, we conducted a one-way repeated measures ANOVA to assess
the neuropsychological performance of children with therapy-related seizures across three time
points: first assessment, end of therapy, and two years post therapy completion. The means and
standard deviations are presented in Table 6. There was no significant change in estimated
intellectual functioning (EIQ) scores across the three time points for children who experienced
seizures (p = .45). A statistically significant difference was found for basic reading scores from
baseline to 2 years post therapy, with a worsening trend (-7.43 points, p = .01). There were no
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significant differences across measurements of math reasoning, attention, working memory, or
processing speed (p = .39; p = .76; p = .38; p = .82, respectively). Freedom from Distractibility
approached significance for a worsening trend from end of treatment to 2 years post (p = .06).
Parental report on the Conners’ indicated significant improvement in Learning from baseline to 2
years post (-19.56 points, p = .01). None of the other Conners’ rating scales revealed significant
differences, although improvements in Hyperactivity approached significance (p = .06).
To address the third study objective, we conducted one-sample t-tests to compare
cognitive performance of children who experienced therapy-related seizures to published
normative scores at each of the three assessment time points. The means and standard deviations
for respective time points are presented in Tables 7, 8, and 9. At first assessment, there was a
statistically significant difference for estimated IQ, with the seizure group having a lower mean
IQ of 89 compared to normative mean IQ of 100, p = .01. There were no significant differences
between the seizure group and normative scores for measures of academics, inattention, or
processing speed. Lastly, at first assessment, the Conners’ Parent Rating Scale revealed
significantly more psychosomatic problems in the seizure group (M = 68.64) than the norm
group (M = 50), p < .01. In comparison to normative scores at end of therapy (week 120),
significant differences for IQ were no longer present; however, the seizure group performed
significantly worse on working memory tasks (FFD = 80.14 vs. 100 norm, p = .02; DS Total =
6.43 vs. 10 norm, p = .03) and their parents reported greater psychosomatic problems (65.00 vs.
50 norm, p = .02). At two years post therapy completion, the same pattern was observed for
working memory as the seizure group performed significantly worse than the norm (FFD = 79.43
vs. 100 norm, p = .01; DS Total = 6.00 vs. 10 norm, p = .02) as well as parental report of
psychosomatic problems (65.70 vs. 50 norm, p = .03).
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We conducted a Mixed Model repeated measures ANOVA (between and within subjects
factors) to compare cognitive performance of children who experienced treatment-related
seizures to the matched cohort of children on protocol without seizures across the three time
points (first assessment, end of therapy, and two years post therapy completion). The means and
standard deviations for respective time points are presented in Tables 10, 11, and 12. At first
assessment, the seizure group demonstrated a significant difference for lower estimated IQ when
compared to the non-seizure cohort group (89.33 vs. 100.74, p = .05). There were no other
significant differences in cognitive functioning or parental report of behavioral problems at first
assessment. In comparison to the non-seizure cohort group at end of therapy (week 120), the
seizure group performed significantly worse on attention and working memory tasks (FFD =
80.14 vs. 100.74, p < .01; DS Total = 6.43 vs. 9.52, p = .05). Parents of children who
experienced therapy-related seizures reported greater learning problems, impulsivity, and
hyperactivity (62.27 vs. 49.69, p = .04; 59.36 vs. 48.65, p = .04; 57.45 vs. 49.59, p = .04,
respectively). At two years post in comparison to the non-seizure cohort group, the seizure group
performed significantly worse on a measure of overall intelligence (FSIQ = 88.92 vs. 101.00, p =
.04). The same pattern of the seizure group performing significantly worse than the non-seizure
cohort group on measures of attention and working memory was observed (FFD = 79.43 vs.
101.17, p < .01; DS Total = 6.00 vs. 10.04, p = .01), with additional processing speed deficits in
the seizure group (PSI = 88.57 vs. 103.92, p = .02). There were no significant elevations on
parental report of behavioral problems for the seizure group in comparison to the non-seizure
cohort group.
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Imaging Comparisons
For the final objective, we used Fisher’s exact test to compare the rates of
leukoencephalopathy classification between children with treatment-related seizures and
similarly treated children without seizures. Results are reported in Table 13. Significant
differences on MRI were observed between the seizure and cohort groups at second time point of
week 7 continuation (56% vs. 12.9%, p < .01) and third time point of end of therapy (week 120:
38% vs. 6%, p = .01) but not at the first imaging time point of week 5 remission (15.38% vs.
2.94%, p = .18).
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DISCUSSION
Results from this study revealed that two-year incidence of therapy-related seizures for
children treated on the TOTXV protocol was 3.82%, which is a relatively positive outcome given
that it falls within the lower range of 3 to 13 percent seizure incidence found in the literature.
This lowered incident rate, in comparison to the larger literature, is likely reflective of the
lessened neurotoxic effect of chemotherapy-only protocols on neurodevelopment and cognitive
late effects. Contrary to a priori hypotheses, demographic or clinical factors such as prior seizure
history or intensity of chemotherapy were not statistically significant predictors of seizure
development. Although, a trend for standard/high treatment intensity was observed for seizure
risk (p = .06). Over 50 percent of seizures observed in this study occurred during the induction
and consolidation phases, consistent with historical findings of seizures during early phases of
treatment in which chemotherapy doses are typically at its highest.
Of particular interest is the notable lack of significant change in neuropsychological
performance for children with therapy-related seizures when compared to themselves across
treatment time points. Measures of overall intellectual functioning, math reasoning, attention,
working memory, and processing speed did not significantly differ from first assessment to two
years post therapy completion. The only exception was performance on a measure of basic
reading, which significantly worsened from first assessment to two years post therapy. One
potential explanation for this contrary finding is that first assessment was not a true baseline, as
four doses of high dose methotrexate (HDMTX) were administered prior to first
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neuropsychological assessment. It is possible that intensified chemotherapy agents were already
influencing cognitive performance at first assessment. This ‘artifact baseline’ hypothesis may
also explain parents’ reports on the CPRS of significantly reduced learning problems from first
assessment to two years post therapy completion. Parents of children with treatment-related
seizures may have already been observing learning problems at first assessment, which they
acclimated to two years post therapy. Another plausible explanation, given that end of therapy
corresponded with school re-entry for many children, is that learning problems may have been
particularly notable for parents at therapy completion (second assessment). School
accommodations and reintegration into the social learning environment may have lessened these
issues over time.
Although there was a broad lack of neuropsychological change within the seizure group
across time, when the neuropsychological performance of the seizure group was compared to
normative sample scores, patterns of differences emerged and maintained across assessment time
points. Significant differences were observed in domains of attention, working memory,
processing speed, and parental report of psychosomatic problems for children with therapyrelated seizures. This finding is consistent with previous literature that supports cognitive late
effects, namely impaired attention and working memory abilities, in children treated for ALL
(Ashford et al., 2010; Conklin et al., 2012; Phipps et al., 2012).
Similar patterns for attention, working memory, and processing speed also emerged
during comparisons of neuropsychological performance across assessments between the seizure
group and the non-seizure cohort. At leukemia therapy completion, children with therapy-related
seizures performed significantly worse for attention and working memory tasks than the matched
cohort, and these deficits persisted two years later with the addition of processing speed deficits.
39

Results also revealed that children with treatment-related seizures performed significantly worse
on a measure of estimated intelligence at first assessment and also on a full-scale measure of
intelligence (FSIQ) at two years post therapy completion when compared to the matched cohort.
The ‘artifact baseline’ hypothesis likely also explains significant differences for estimated
intellectual functioning at first assessment. However, the finding for decreased overall
intelligence at two years post therapy alongside problems in attention, working memory, and
processing speed deficits is of particular interest. Given these concurrent findings, it is possible
that early cognitive late effects of attention and working memory problems among children who
experienced on-therapy seizures may precede later declines observed in overall IQ. It is
important to also mention that at therapy completion, the seizure group parents reported
significantly more problems with learning, impulsivity, and hyperactivity than parents of nonseizure cohorts, but these differences become insignificant by two years post therapy completion
as group scores are nearly the same. As aforementioned, end of therapy corresponds with schoolreentry for many children, such that learning and behavioral problems may be even more salient
for parents of children with treatment-related seizures, which lessen over time with school
accommodations.
This study’s imaging findings indicated that children with therapy-related seizures
experienced more significant early neurotoxicity (i.e., leukoencephalopathy as indicated by white
matter hyperintensities on MRI) than non-seizure cohorts, which likely contributes to higher
levels of cognitive late effects observed among children with on-therapy seizures. Further
supporting the early cognitive late effect hypothesis, significant differences in treatment-induced
leukoencephalopathy between the seizure group and cohort group were observed concurrently
with significantly worse neuropsychological performance for the seizure group in comparison to
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the cohort group on measures of estimated intellectual functioning, attention, and work memory.
This observation is consistent with previous empirical findings of decreased abilities on attention
and working memory tasks to be associated with treatment-related neuroanatomical changes
such as smaller and abnormal cerebral white matter volumes (Ashford et al., 2010; Khong et al.,
2006; Reddick et al., 2005a; Reddick et al., 2006). Smaller white matter tissue volumes have also
been related to larger declines in intelligence and academics (Reddick et al., 2006).
Rates of leukoencephalopathy prevalence for this study were also consistent with
previous literature indicating a rise in white matter lesions after several intravenous HDMTX
rounds, followed by reductions in white matter damage at therapy completion (Reddick et al.,
2005). Therefore, the observed abnormal structural brain changes in cerebral white matter are
likely subsequent to on-therapy vascular-related injuries, namely a form of HDMTX
encephalopathy (Lövblad et al., 1998). While metabolic factors and arterial hypertension
undoubtedly play a role in seizure risk, leukoencephalopathy is a probable common etiology of
treatment-related seizures in this study.
A major implication of these neurocognitive findings for children who experienced
therapy-related seizures while treated for ALL is the provision of preliminary yet promising
information that may assist with treatment planning, monitoring of cognitive outcomes, and
caregiver education, all with the ultimate end goal of improving quality of life for this growing
group of survivors. Based on this study’s observations, it appears that children who experienced
treatment-related seizures are at greater neurocognitive risk when compared to matched cohorts
without seizures. The task then presented is to detect how and when we can best identify
significant changes in neurocognitive status that indicate risk for long-term CNS effects.
Performance-based and imaging-based measures have demonstrated to be sensitive and specific
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indicators of neurotoxicity. Utilizing these methods as appropriate in the early phases of
chemotherapy, coupled with sophisticated clinical observation (e.g., seizure occurrence as
treatment intensifies), is likely to lead to earlier detection of children at risk for CNS effects.
Earlier detection would allow for earlier interventions and treatment modifications that may
mitigate the neurotoxic effects of high-dose chemotherapy on the neurodevelopment of
childhood cancer survivors.
Domain-specific neuropsychological testing combined with more advanced
neuroimaging such as magnetic resonance diffusion tensor imaging (DTI) may help in the early
identification of subtle cerebral white matter damage. The earliest identification of even subtle
changes in neurocognitive status could make the utmost difference for medical researchers and
physicians developing more effective therapies that result in fewer cognitive late effects and
mitigate other side effects such as leukoencephalopathy and seizures. Identification would better
inform each patients’ treatment plan with enhanced physician insight on when regimen-related
accommodations are needed, such as modifying the timing or dosing of chemotherapy
administrations to minimize white matter damage or seizure risk without sacrificing a favorable
prognosis. Identification would also allow healthcare professionals to develop patient-centric
medical regimens that not only implement therapeutic interventions targeted at domain-specific
cognitive rehabilitation, but enact preventative therapy that may serve as a cognitive protective
factor against lasting therapy-related CNS impairments. For patients and their caregivers, early
identification of treatment-related neurocognitive deficits would allow them to develop
compensatory and remedial strategies to minimize therapy-related impairments, which is likely
to result in improved prognosis and reintegration into classroom and social settings.
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Recent empirical findings for neurocognitive interventions that lessen cognitive late
effects appear promising for the expanding cancer survivorship population. These interventions
comprise pharmacologic and non-pharmacologic methods that rely heavily on the cognitive
rehabilitation literature for traumatic brain injury, childhood ADHD, and dementia (Davis et al.,
2013; Phipps et al., 2012). Psychostimulant medication used to mitigate attention deficits in
children diagnosed with ADHD, specifically methylphenidate (MPH), has demonstrated similar
positive attentional benefits in childhood cancer survivors (Conklin et al., 2007; Davis et al.,
2013; Mulhern et al., 2004; Thompson et al., 2001). Medications used to treat mild to moderate
dementia, such as donepezil, have also been under examination and preliminary results suggest
improvement in cognitive function as well as mood and health-related quality of life (Castellino
et al., 2012; Shaw et al., 2006). There is also a movement towards using pharmacological
interventions as neuroprotective agents during treatment, such as the anti-Alzheimer drug
memantine to prevent cognitive decline related to oxidative stress in the CNS (Brown et al.,
2012). However, medication side effects, parental disapproval, and medical contraindications
may interfere with the feasibility pharmacological interventions. Non-pharmacological
interventions such as the Cognitive Remediation Program (CRP, Butler & Copeland, 2002) and
CogMed© Working Memory Training (Klingberg et al., 2002; Klingberg et al., 2005) have
developed as an alternative to medication. Butler and colleagues (2008) multicenter, randomized
clinical trial of CRP produced promising results for 167 childhood cancer survivors, including
modest effect size within the .5 range, parental report of significant improvements in attention,
and gains on measures of academic abilities in language and mathematics. CogMed’s welldemonstrated efficacy for remediation of attention deficits in children diagnosed with ADHD has
encouraged researchers to begin exploring this targeted working memory program in childhood
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cancer survivors (Conklin et al., 2013; Hardy, Carlson-Green, & Conklin, 2012; Hardy, Willard,
Allen, & Bonner, 2012). While a computer-based treatment is favored due to its portable nature
and limited staffing needs, research continues to investigate the feasibility, generalizability, and
continuation of benefits following computerized intervention. The Pediatric Cancer Genome
Project, led by St. Jude Children’s Research Hospital and Washington University School of
Medicine, also offers hope of identifying genetic markers of greater risk for cognitive late effects
in those diagnosed with ALL.
Limitations and Future Directions
The current findings should be interpreted within the context of study limitations. One
limitation of this study is its retrospective nature. A prospective, longitudinal study would allow
for a more systematic investigation of the emergence of cognitive late effects, including potential
mechanisms of change. Efforts are directed toward conducting earlier baseline assessments, yet
this is difficult due to children being sick, needing immediate medical treatment, and receiving
high-dose steroids. None of which are positive factors for valid and reliable estimates of
cognitive function. Future studies would also benefit from timing neuropsychological
assessments to correspond with neuroimaging assessments for more exact comparisons.
Likewise, for this study, an additional imaging time point at two years post therapy would have
been helpful in examining whether hypothesized declines in leukoencephalopathy, which were
observed at end of treatment in our sample, continue beyond therapy completion.
In regard to study measures, although EIQ is highly correlated with FSIQ, the use of an
estimated intelligence measure at first assessment likely limited sensitivity to detect
neurocognitive changes in overall intellectual functioning. It also made comparisons to later
assessments of full-scale intellectual functioning less appropriate. Careful replication of the
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finding for declines in overall intelligence with sensitive measures throughout is warranted. It
was also difficult to interpret CPRS findings as they were often inconsistent with neurocognitive
performance scores. The lack of correlation between parent report and performance-based
measures may be one of the unfortunate yet expected drawbacks of subjective rater measures,
which have previously been shown to exhibit low rates of sensitivity and specificity for
performance-based changes in childhood cancer populations (Howarth et al., 2013). While it
could be that problematic child behaviors such as learning difficulties and hyperactiveimpulsivity significantly alleviated post-treatment, it may also be that parents are relatively
limited to gross assessments of behavioral changes, relying on salient factors such as grades in
school or misconduct within the school and home environments.
In recent years, neuroimaging methods have advanced from basic structural MRI to more
sophisticated techniques, such as magnetic resonance spectroscopy, volumetrics, and diffusion
tensor imaging (DTI). Future studies will benefit from DTI specifically as it enables the
examination of location, orientation, and anisotropy of white matter pathways associated with
neuroanatomical models of attention and memory, such as the prefrontal cortex, in relation to
chemotherapy-induced cognitive late effects. Preliminary findings of DTI studies indicate greater
frontal white matter changes after chemotherapy than before treatment in children treated for
hematological malignancies, such as ALL (Morioka et al., 2013). Decreased white matter
diffusion anisotropy observed after cancer treatment has also been associated with significant
negative effects on IQ (Khong et al., 2006). A recent review of DTI within the context of
chemotherapy-induced neurocognitive impairment, drawing from longitudinal and crosssectional data, indicates that current studies confirm the relationship between abnormal cerebral
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white matter and impaired cognitive performance (Deprez, Billiet, Sunaert, & Leemans, 2013).
Therefore, assessment of white matter pathways via DTI is likely to be a valuable clinical tool
for measurement of treatment-induced neurotoxicity in childhood cancer survivors.
Conclusions
There has been growing empirical evidence of cognitive late effects for survivors of acute
lymphoblastic leukemia. While demographic and clinical factors have been associated with
greater likelihood of cognitive late effects in leukemia therapy (i.e., younger age at diagnosis,
female gender, higher treatment intensity, and greater time since treatment), this study’s aim was
to understand the impact of treatment-related seizures as an indicator of neurotoxicity with
associated cognitive decline and subsequent cognitive late effects.
Despite this study’s limitations, the current findings point to a relationship between ontherapy seizures, leukoencephalopathy, and deficits in neuropsychological functioning,
specifically attention, working memory, and processing speed skills, which may lead to overall
declines in intellectual functioning. However, these findings also raise questions about the
neurobehavioral mechanisms, including neuroanatomical pathways, involved in cognitive late
effects associated with seizures. Future research on theoretically driven neurobehavioral
processes is necessary to unravel these mechanisms within the context of leukemia therapy so
that we may improve caregiver education, treatment planning, and treatment monitoring for as
many children as possible.
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Table 1
Means, Standard Deviations, Medians, and Ranges of Ages Across Groups at Diagnosis

N

Total

Seizure Group

Cohort 1

Cohort 2

p-value

57

19

19

19

0.99A

8.27 (4.80)

8.26 (4.81)

8.23 (4.82)

7.21

8.00

7.66

2.07-18.73

2.09-17.12

2.14-18.73

Mean (SD) 8.26 (4.72)
Median
Range
A

7.66
2.07-18.73

Analysis of Variance
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Table 2
Race, Gender, and Treatment Intensity Across Groups at Diagnosis

N

Total

Seizure Group

Cohort 1

Cohort 2

57

19

19

19
0.68P

Race [n (%)]
White

42 (73.7)

14 (73.7)

13 (68.4)

15 (78.9)

Black

14 (24.6)

5 (26.3)

5 (26.3)

4 (21.1)

Other

1 (1.8)

0 (0)

1 (5.3)

0 (0)
0.99P

Gender [n (%)]
Male

39 (68.4)

13 (68.4)

13 (68.4)

13 (68.4)

Female

18 (31.6)

6 (31.6)

6 (31.6)

6 (31.6)
0.99P

Treatment Intensity [n (%)]
Low

P

p-value

21 (36.8)

7 (36.8)

7 (36.8)

7 (36.8)

Stand/High 36 (63.2)

12 (63.2)

12 (63.2)

12 (63.2)

Pearson’s Chi-Square Test
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Figure 1

Probability

Cumulative Incidence of ≥Grade 3 Seizures on TOTXV
0.13
0.12
0.11
0.1
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0

0.032

0

1

Year on Study

71

0.038

2

Table 3
Cumulative Incidence of Seizures by Relevant Factors
Factors

N

Year 1

Year 2

0.15G

Age at Diagnosis
<5 Yrs

235

1.3 ± 0.7

2.6 ± 1.0

Others

263

4.9 ± 1.3

4.9 ± 1.3
0.33G

Race
White

402

2.7 ± 0.8

3.5 ± 0.9

Black

79

6.3 ± 2.8

6.3 ± 2.8

Other

17

0

0
0.27G

Gender
Male

279

3.9 ± 1.2

4.7 ± 1.3

Female

219

2.3 ± 1.0

2.7 ± 1.1
0.06G

Treatment Intensity

G

p-value

Low

284

1.4 ± 0.7

2.5 ± 0.9

Stand/High

214

5.6 ± 1.6

5.6 ± 1.6

Gray’s Test

72

Table 4
Total Dose of Drug (mg/m 2) Received Before First Seizure Event Across Groups
Total (n=57)

Seizure Group (n=19)

Cohorts (n = 38)

DEX
Mean (SD)
Max

0.96
151.37 (232.34)
866.62

149.36 (234.15)

152.38 (234.58)

858.17

866.62

HDMTX
Mean (SD)
Max

0.25
11070.73 (8780.95)

9193.60 (7840.70)

120009.29 (9169.41)

32263.77

26401.27

32263.77

ITHMA
Mean (SD)
Max

p-value

0.45
69.64 (47.33)

62.94 (46.09)

73.00 (48.19)

144.00

132.00

144.00
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Table 5
Frequency Count and Percent of Seizure Onset Across Treatment Phases
Frequency

Percent

Pre-Treatment

1

5.26%

Induction

5

26.32%

Consolidation

5

26.32%

Continuation Weeks 1-6

1

5.26%

Continuation Weeks 10-16

3

15.79%

Continuation Weeks 48-95

1

5.26%

LR Continuation Weeks 20-47

2

10.53%

LR Continuation Weeks 21-47

1

5.26%

74

Table 6
Means and Standard Deviations on Cognitive Measures for Seizure Group Across Time Points
First Assess (Wk 6)

End Therapy (Wk 120)

2 Yrs Post

p-value

Wechsler EIQ

89.33 (10.10)

90.73 (19.82)

94.33 (18.84)

0.45

Wechsler FSIQ

--

88.20 (21.29)

88.92 (18.35)

--

FFD

--

80.14 (17.86)

79.43 (15.11)

0.06

PSI

--

86.29 (24.31)

88.57 (18.04)

0.82

DS Total

--

6.43 (3.60)

6.00 (4.00)

0.38

93.33 (7.39)

90.80 (22.38)

86.56 (22.26)

0.01*

91.83 (16.79)

87.00 (19.30)

89.67 (22.47)

0.39

86.15 (21.79)

89.43 (12.69)

83.04 (21.33)

0.76

51.04 (9.69)

50.84 (13.81)

53.27 (15.59)

0.92

Learning

63.27 (23.43)

62.27 (18.66)

44.00 (9.21)

0.01*

Psychosomatic

68.64 (17.29)

65.00 (19.54)

65.70 (20.39)

0.74

Impulse-Hyper

56.36 (15.36)

57.45 (11.47)

50.50 (9.81)

0.28

Hyperactive

59.73 (20.56)

59.36 (17.03)

46.60 (9.34)

0.06

WIAT
Basic Reading
Math Reasoning
Conners’ CPT
Omissions
Hit RT
CPRS

75

Table 7
Comparisons on Cognitive Measures Between Seizure Group and Normative Sample at First
Assessment (Week 6)
Seizure Group

Normative Sample

p-value

89.33 (3.37)

100 (15)

0.01*

Basic Reading

93.33 (3.02)

100 (15)

0.07

Math Reasoning

91.83 (6.61)

100 (15)

0.27

Omissions

86.15 (9.75)

84 (6)

0.83

Hit RT

51.04 (4.33)

50 (10)

0.82

Learning

63.27 (7.06)

50 (10)

0.08

Psychosomatic

68.64 (5.21)

50 (10)

< 0.01*

Impulse-Hyper

56.36 (4.63)

50 (10)

0.19

Hyperactive

59.73 (6.20)

50 (10)

0.14

Wechsler EIQ
WIAT

Conners’ CPT

CPRS
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Table 8
Comparisons on Cognitive Measures Between Seizure Group and Normative Sample at End of
Therapy (Week 120)
Seizure Group

Normative Sample

p-value

Wechsler EIQ

90.73 (5.98)

100 (15)

0.15

Wechsler FSIQ

88.20 (6.73)

100 (15)

0.11

FFD

80.14 (6.75)

100 (15)

0.02*

PSI

86.29 (9.19)

100 (15)

0.18

DS Total

6.43 (1.36)

10 (3)

0.03*

Basic Reading

90.80 (7.08)

100 (15)

0.22

Math Reasoning

87.00 (6.10)

100 (15)

0.06

Omissions

89.43 (4.23)

84 (6)

0.23

Hit RT

50.84 (4.60)

50 (10)

0.85

Learning

62.27 (5.62)

50 (10)

0.05*

Psychosomatic

65.00 (5.89)

50 (10)

0.02*

Impulse-Hyper

57.45 (3.46)

50 (10)

0.05*

Hyperactive

59.36 (5.14)

50 (10)

0.09

WIAT

Conners’ CPT

CPRS
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Table 9
Comparisons on Cognitive Measures Between Seizure Group and Normative Sample at Two
Years Post-Therapy
Seizure Group

Normative Sample

p-value

Wechsler EIQ

94.33 (5.44)

100 (15)

0.31

Wechsler FSIQ

88.92 (5.30)

100 (15)

0.06

FFD

79.43 (5.71)

100 (15)

0.01*

PSI

88.57 (6.82)

100 (15)

0.14

DS Total

6.00 (1.41)

10 (3)

0.02*

Basic Reading

86.56 (7.42)

100 (15)

0.10

Math Reasoning

89.76 (7.49)

100 (15)

0.20

Omissions

83.04 (6.43)

84 (6)

0.88

Hit RT

53.27 (4.70)

50 (10)

0.50

Learning

44.00 (2.91)

50 (10)

0.06

Psychosomatic

65.70 (6.45)

50 (10)

0.03*

Impulse-Hyper

50.30 (3.10)

50 (10)

0.92

Hyperactive

46.60 (2.95)

50 (10)

0.27

WIAT

Conners’ CPT

CPRS
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Table 10
Comparisons on Cognitive Measures Between Seizure Group and Matched Cohort at First
Assessment (Week 6)
Seizure Group

Cohort Group

p-value

89.33 (3.37)

100.74 (3.18)

0.05*

Basic Reading

93.33 (3.02)

102.45 (3.09)

0.10

Math Reasoning

91.83 (6.61)

104.65 (3.28)

0.08

Omissions

86.15 (9.75)

72.49 (6.86)

0.22

Hit RT

51.04 (4.33)

44.42 (3.31)

0.37

Learning

63.27 (7.06)

50.03 (1.71)

0.19

Psychosomatic

68.64 (5.21)

67.17 (3.30)

0.74

Impulse-Hyper

56.36 (4.63)

50.23 (1.73)

0.22

Hyperactive

59.73 (6.20)

49.13 (1.57)

0.17

Wechsler EIQ
WIAT

Conners’ CPT

CPRS

79

Table 11
Comparisons on Cognitive Measures Between Seizure Group and Matched Cohort at End of
Therapy (Week 120)
Seizure Group

Cohort Group

p-value

Wechsler EIQ

90.73 (5.98)

100.41 (2.81)

0.14

Wechsler FSIQ

88.20 (6.73)

97.61 (2.29)

0.21

FFD

80.14 (6.75)

100.74 (2.67)

< 0.01*

PSI

86.29 (9.19)

100.74 (3.37)

0.14

DS Total

6.43 (1.36)

9.52 (0.50)

0.05*

Basic Reading

90.80 (7.08)

102.04 (2.62)

0.22

Math Reasoning

87.00 (6.10)

100.46 (2.45)

0.07

Omissions

89.43 (4.23)

84.42 (3.26)

0.51

Hit RT

50.84 (4.60)

47.42 (1.90)

0.50

Learning

62.27 (5.62)

49.69 (2.35)

0.04*

Psychosomatic

65.00 (5.89)

56.41 (3.19)

0.16

Impulse-Hyper

57.45 (3.46)

49.59 (2.08)

0.04*

Hyperactive

59.36 (5.14)

48.66 (2.03)

0.04*

WIAT

Conners’ CPT

CPRS
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Table 12
Comparisons on Cognitive Measures Between Seizure Group and Matched Cohort at Two Years
Post-Therapy
Seizure Group

Cohort Group

p-value

Wechsler EIQ

94.33 (5.44)

101.64 (2.87)

0.29

Wechsler FSIQ

88.92 (5.30)

101.00 (2.77)

0.04*

FFD

79.43 (5.71)

101.17 (3.58)

< 0.01*

PSI

88.57 (6.82)

103.92 (2.59)

0.02*

DS Total

6.00 (1.41)

10.04 (0.68)

0.01*

Basic Reading

86.56 (7.42)

101.53 (2.79)

0.07

Math Reasoning

89.76 (7.49)

100.20 (2.65)

0.22

Omissions

83.04 (6.43)

78.32 (3.18)

0.19

Hit RT

53.27 (4.70)

52.52 (1.97)

0.61

Learning

44.00 (2.91)

46.71 (2.76)

0.37

Psychosomatic

65.70 (6.45)

68.71 (3.94)

0.48

Impulse-Hyper

50.30 (3.10)

47.00 (2.66)

0.35

Hyperactive

46.60 (2.95)

47.47 (3.35)

0.70

WIAT

Conners’ CPT

CPRS
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Table 13
Comparisons of Leukoencephalopathy on MRI Between Seizure Group and Matched Cohort
Across Time Points
Seizure Group

Cohort Group

Baseline [n (%)]

p-value
0.18

Leuko

2 (15.38)

1 (2.94)

Normal

11 (84.62)

33 (97.06)

Week Post-First Assessment [n (%)]

< 0.01*

Leuko

9 (56.25)

4 (12.90)

Normal

7 (43. 75)

27 (87.10)

End of Therapy [n (%)]

0.01*

Leuko

5 (38.46)

2 (6.06)

Normal

8 (61.54)

31 (93.94)
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Education
2014

Doctor of Philosophy, Clinical Psychology
The University of Mississippi, University, MS
Doctoral Dissertation: Neurocognitive Outcomes in Children Experiencing
Seizures During Treatment for Acute Lymphoblastic Leukemia
Advisors: Kelly G. Wilson, Ph.D.; Heather M. Conklin, Ph.D.

2014-2013 APA Approved Pre-Doctoral Internship, Clinical Medical/Health Psychology
The University of Florida, Health Science Center, Gainesville, FL
Director of Internship Training: Dr. Lori B. Waxenberg, Ph.D., ABPP
2011

Master of Arts, Clinical Psychology
The University of Mississippi, University, MS
Master’s Thesis: Discriminating Emotions and Engaging Difficult
Emotional Material: Implications for Process and Outcome in Written
Disclosure
Advisor: Kelly G. Wilson, Ph.D.

2004

Bachelor of Science, Magna Cum Laude
Spring Hill College, Mobile, AL
Major: Psychology
Minor: Philosophy
Senior Thesis: The Effects of Personality Type on Procrastination in
College Students
Advisor: Lisa D. Hager, Ph.D.
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Research Experience
2013-2011 Principal Investigator
Cognitive Outcomes in Children Experiencing Seizures during Treatment for
Acute Lymphoblastic Leukemia (XPD11-032)
St. Jude Children’s Research Hospital, Memphis, TN
 conducted a retrospective study to explore neuropsychological outcomes
and neuroimaging findings in children experiencing seizures during
leukemia treatment
Supervisor: Heather M. Conklin, Ph.D.

2012-2010 Clinical Research Assistant to Heather M. Conklin, Ph.D.
Computerized Intervention for Amelioration of Cognitive Late Effects Among
Childhood Cancer Survivors (COGTRN)
St. Jude Children’s Research Hospital, Memphis, TN
 ClinicalTrials.gov Identifier: NCT01217996
 conducted archival data collection, electronic database searches, data entry
and manipulation, quality assurance checks, literature searches,
recruitment calls, eligibility checklists, participant scheduling,
neuropsychological testing (cognitive, achievement, memory, attention,
executive functioning), protocol scoring and interpretation
Supervisor: Heather M. Conklin, Ph.D.
2011-2009 Principal Investigator
Investigating the Expressive Writing Paradigm
The University of Mississippi, University, MS
 investigated the effects of writing about emotionally traumatic events vs.
writing about personal values on psychological processes and outcomes
Supervisor: Kelly G. Wilson, Ph.D.
2009

Co-Investigator
Mindfulness for Two: Manipulating the Therapist and Context
The Psychological Services Center, University of Mississippi, University, MS
 investigated the effects of therapist and contextual manipulations on
interviewers’ and interviewees’ personal experiences (e.g., mood, physical
sensations, quality of interaction)
Supervisor: Kelly G. Wilson, Ph.D.

2009

Research Assistant to Catherine H. Adams, M. A.
Perspective-Taking Among People with Intellectual Disabilities
The Baddour Center, Senatobia, MS
 trained adults with developmental disabilities in deictic framing and
perspective taking for Theory of Mind tasks and social skills interactions
Supervisor: Kelly G. Wilson, Ph.D.
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2008

Co-Investigator
An Examination of the Stability of Implicit Relational Assessment Procedure
(IRAP) Performance over Repeated Administrations
The University of Mississippi, University, MS
 examined the reliability, validity, and procedural integrity the IRAP, a
computerized measure of implicit cognition
Supervisor: Kelly G. Wilson, Ph.D.

2008

Applied Behavior Analysis Trainer
Acceptance and Commitment Training (ACT) to Address Burnout and Stress in
Staff Working with People with Intellectual Disabilities
North Mississippi Regional Center (NMRC), Oxford, MS
 trained NMRC staff in ABA techniques across three weeks
 collected pre- & post-data
Supervisor: Kelly G. Wilson, Ph.D.

2008

Co-Investigator
Psychological Struggle and Flexibility
The University of Mississippi, University, MS
 conducted survey research investigating the relationships across measures
of psychological flexibility, valued living, mindfulness, body image,
eating behaviors, academic procrastination, and established measures of
psychological distress/outcome
Supervisor: Kelly G. Wilson, Ph.D.

2007

ACT Luckyday Scholars Group Facilitator
The University of Mississippi, University, MS
 facilitated group discussions with undergraduate Luckyday Scholars
having academic difficulties utilizing various Acceptance and
Commitment Training exercises; collected time-series data
Supervisor: Kelly G. Wilson, Ph.D.

2006-2005 Co-Investigator
Investigating the Emotional Writing Paradigm: An Analysis of Experimenter
Interaction and Individual Experience of Emotion
The University of Mississippi, University, MS
 investigated the effects of therapist manipulations on individuals’
experiences of emotion and psychological outcome
 coded, entered, and analyzed written narratives into Linguistic Inquiry
Word Count (LIWC) Program Software
Supervisor: Kelly G. Wilson, Ph.D., Leslie J. Rogers, M.A.
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2005-2004 Research Assistant to Kelly G. Wilson, Ph.D.
The University of Mississippi, University, MS
Part-time position
 aided in revising Clinic IRB application
 assisted in data collection and running studies for senior lab members’
thesis & dissertation projects
2004

Principal Investigator
Spring Hill College, Mobile, AL
 investigated the effects of personality type on measures of academic
procrastination and task completion
Supervisor: Lisa D. Hager, Ph.D.

Teaching and Administrative Experience
Sprg 2010 Co-Instructor, PSY 420: Special Topics in Psychology
The University of Mississippi, University, MS
 assisted students in gaining research experience beyond their laboratory
class with a special emphasis in clinical psychophysiology
 aided students in preparing materials for graduate school applications
Supervisor: Scott A. Gustafson, Ph.D.
Fall 2010 Guest Lecturer, Introductory Psychology, Social Psychology Module
The University of Mississippi, University, MS
2010-2008 Assistant Director
Part-time position
The Psychological Services Center, University of Mississippi, University, MS
 assisted Director with daily management of clinic
 provided quality assurance reviews of clinic records
 marketed and advertised services; increased community relations
 organized and monitored clinic duties and emergency cell phone duties
 organized and tracked individual supervision team’s client flow
 oriented and trained incoming graduate therapists on clinic protocol
 revised clinic manual and streamlined procedures
 surveyed experts for treatment manuals to be included in the resource
library
Supervisor: Scott A. Gustafson, Ph.D.
2010-2008 Executive Team Leader
The Psychological Services Center, University of Mississippi, University, MS
 improved quality of clinical training, services, and clinic facilities
 recorded client activity to assist with triage
 brainstormed and implemented marketing and advertising ideas
Supervisor: Scott A. Gustafson, Ph.D.
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2008-2007 Senator, Graduate Student Council
The University of Mississippi, University, MS
 served as liaison between psychology department and graduate school
2008-2007 Clinic Administrative Group Member, Feng Shui
The Psychological Services Center, University of Mississippi, University, MS
 served as liaison between clinic group and supervision team
 kept records of client activity
 managed funds to update clinic equipment and decor
Supervisor: D. Scotty Hargrove, Ph.D.
2007

Seminar on College Teaching
The University of Mississippi, University, MS
 joined and contributed to the Society for the Teaching of Psychology
listserv
 created a syllabus for a 15 wk course in Abnormal Psychology
 prepared and delivered an Abnormal Psychology lecture to a small number
of students (n=25) which incorporated explicit learning objectives, active
learning techniques, outcome measures, and exam questions in which all
levels of learning were assessed
 provided peer reviews for colleagues’ lectures and received peer reviews
 created a teaching portfolio with statement of Teaching Philosophy
Supervisor: Kenneth J. Sufka, Ph.D.

2004

Teaching Assistant to Kelly G. Wilson, Ph.D.
The University of Mississippi, University, MS
Part-time fall position
 administered and graded examinations and extra credit for an
undergraduate Abnormal Psychology class
 created class study guides for test preparation purposes

Clinical Experience
2014-2013 Clinical Medical/Health Psychology Intern
The University of Florida, Health Science Center, Gainesville, FL
 conducted semi-structured diagnostic assessments, primary caregiver
interviews, neuropsychological testing, brief and long-term evidencebased treatments, with a variety of inpatient and outpatient medical
populations, as well as ongoing supportive psychosocial services for
families, across the following rotations:
• Transplant Psychology, Acute Adult Neurotrauma, PsychoOncology, Chronic Pain/GI/Primary Care, Women’s Health,
Rehabilitation Health, Adult Neuropsychology, Behavioral Sleep
Medicine, and Child Health
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 authored integrated neuropsychosocial reports and EPIC medical records
Supervisors: Glenn S. Ashkanazi, Ph.D.; Robert T. Guenther, Ph.D., ABPP
(RP); Deidre Pereira, Ph.D.; Lori B. Waxenberg, Ph.D., ABPP; Patricia E.
Durning, Ph.D.; Thomas R. Kerkhoff, Ph.D., ABPP (RP); Nicole E.
Whitehead, Ph.D.; Duane A. Dede, Ph.D.; David Janicke, Ph.D.; Christina S.
McCrae, Ph.D.
Pres-2004 ACT Treatment Development Group (ACTTDG)
The University of Mississippi, University, MS
 developing expertise in the ACT model of assessment, case
conceptualization, and treatment
 co-developing a training model that mixes didactic and experiential
components
 observing, consulting, and supervising peer therapists
Supervisor: Kelly G. Wilson, Ph.D.
2013-2012 Provisionally Certified Mental Health Therapist
Batesville Crisis Stabilization Unit, Batesville, MS
 conducted intakes, individual therapy, and group therapy sessions with an
adult acute inpatient population presenting with active psychosis, suicidal
and homicidal ideation
 completed intake paperwork including DSM-IV-TR diagnoses, targeted
behaviors of change, and elaborated behavioral treatment plans
 authored individual and group therapy notes
Supervisors: Julie Garner, M.Ed., L.P.C., Director; Scott A. Gustafson, Ph.D.
2013-2005 Graduate Student Therapist
The Psychological Services Center, University of Mississippi, University, MS
 conducted screening, intake, and therapy sessions with clients
 authored therapy notes and completed other psychological documents
 trained in Acceptance and Commitment Therapy (ACT) and Cognitive
Behavioral Therapy (CBT)
Supervisors: Kelly G. Wilson, Ph.D. (2005-Present); Laura R. Johnson, Ph.D.
(2006-2007; 2008-2009); Alan M. Gross, Ph.D. (2007-2008); Todd A.
Smitherman, Ph.D. (2010-2011); Scott A. Gustafson, Ph.D. (2011-2012); Tom
Lombardo, Ph.D. (2012-2013)
2010

Group Facilitator, Coping With College Life
The Psychological Services Center, University of Mississippi, University, MS
 facilitated five one-hour group meetings for college students adjusting to
college life/stressors
 utilized Acceptance and Commitment Training Model
 incorporated present moment, mindfulness, cognitive defusion, and
values-centered exercises
Supervisor: Kelly G. Wilson, Ph.D.
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2010-2009 Behavioral Consultant
Behavior, Attention, and Developmental Disabilities Consultants, LLC
Clarksdale Municipal School District, Clarksdale, MS
 conducted psychological assessments with children and adolescents, and
authored detailed psychological reports
 conducted psychological/behavioral consultations and functional behavior
analysis consultations for numerous elementary, middle, and high schools
within Coahoma County
 conducted client history reviews, multiple-setting client observations,
structured interviews with teachers, parents, and client, analyzed functions
of client behavior, made recommendations, and wrote formal reports
detailing consultation
Supervisor: Emily Thomas Johnson, Ph.D.
2010-2009 Mental Health Consultant
ICS, MS Head Start Centers
 conducted classroom observations of teacher-student interactions
 conducted individual child behavioral observations and assessments
 developed and implemented behavioral intervention plans for children
 engaged in classroom consultation with teachers, aides, and parent
consultation
Supervisor: Alan M. Gross, Ph.D.
2009-2008 Cultural Connections Ambassador
The Counseling Center, The University of Mississippi, University, MS
 facilitated a weekly two hour group comprised of American and
international students
 assisted international students with acculturation process
Supervisor: Laura R. Johnson, Ph.D.
2009-2008 Behavioral Consultant
Part-time position
Desoto County School System, Olive Branch, MS
 conducted psychological assessments with children and adolescents, and
authored detailed psychological reports
 conducted psychological/behavioral consultations and functional behavior
analysis consultations for numerous elementary, middle, and high schools
within Desoto County
 conducted client history reviews, multiple-setting client observations,
structured interviews with teachers, parents, and client, analyzed functions
of client behavior, made recommendations, and wrote formal reports
detailing consultation
Supervisors: Sheila Williamson, Ph.D.; Emily Thomas Johnson, Ph.D.
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2008-2007 Neurohealthrehabilitative Psychology Intern
Behavioral Health Center, North Mississippi Medical Center, Tupelo, MS
Part-time position
 conducted pain evaluations, competency and dementia evaluations,
adolescent drug overdose evaluations, personality assessments, and
neuropsychological assessments with adults and geriatric population
 authored and dictated neuropsychosocial reports
 conducted psychosocial intakes, individual therapy sessions, and group
therapy sessions with inpatients on Acute A, Acute B, Geriatric, and
Chemical Dependency Units
Supervisors: Mike Oliver, Ph.D.; Thomas E. Witty, Ph.D.; Brian Thomas, Psy.D.
2007

Summer Graduate Student Therapist
The Psychological Services Center, University of Mississippi, University, MS
Quarter-time position
 conducted screening, intake, and therapy sessions with clients
 authored therapy notes and completed other psychological documents
Supervisor: D. Scotty Hargrove, Ph.D.

2007-2006 Neuropsychological Examiner
Center for Pediatric Neuropsychology, Le Bonheur Children’s Hospital,
Memphis, TN
Part-time position
 conducted over 50 neuropsychological assessments with infants, toddlers,
children, adolescents, and a few adults
 conducted evaluations within the Epilepsy Monitoring Unit (EMU) and
Spina Bifida Clinic
 authored over 50 detailed neuropsychological reports including DSM-IVTR diagnoses and recommendations
Supervisor: Vickie R. Brewer, Ph.D.
2006-2005 Community Home Graduate Student Psychologist
North Mississippi Regional Center, Oxford, MS
Part-time position
 conducted cognitive and adaptive functioning assessments, weekly
counseling sessions, and data collection with MR community clients
 authored behavioral programs and psychological reports
Supervisors: Kimberly Sallis, Ph.D.; Doug Buglewicz, M.Ed.
2004-2003 Behavioral Specialist
BayPointe Hospital, Mobile, AL
Part-time position
 supervised behaviorally and emotionally disturbed female adolescents
 therapeutically assisted adolescents with daily living skills
Supervisor: Angela Ferrera, M.S., L.P.C., Coordinator of Clinical Services
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2003

Psychology Intern
Therapy Associates, Mobile, AL
Part-time position
 assisted with scheduling clients and clinical filing, observed and
participated in therapy sessions, and created an anger management game
for children
Supervisors: Dodie Ward, M.S., L.P.T.; Kim Zweifler, Ph.D.

2003-2000 Physical Therapist Aide
Providence Hospital, Mobile, AL
Part-time position
 scheduled and transported patients; aided in wound care dressing removal
and application, aided in gait training and therapeutic exercises
 utilized hospital software MediServe and Invision; retrieved medical
records, lab results, supplies, and medications
Supervisors: Loverette Vaughn, Office Coordinator; Kathy Mignone, P.T.A.

Professional Training
2010
ACT Summer Institute at the University of Nevada, Reno
2009
Vincent Carbone’s Verbal Behavior Therapy at Hernando Elementary School,
Hernando, MS
2008
ACT Summer Institute at the Illinois Institute of Technology, Chicago, IL
2007-2006 Center for Pediatric Neuropsychology Rounds at Le Bonheur Children’s Medical
Center, Memphis, TN
2006
ACT Advanced Practice Workshop at The University of Mississippi, University,
MS
2005
ACT Experiential Workshop at Camp Hopewell, Oxford, MS
2004
ACT Summer Institute and Introductory Experiential Workshop at the University
of Nevada, Reno

Grants
Gustafson, S., & Nassar, S. L. (2010). Clinical Training: Creation of a Service Consortium.
United States Department of Health and Human Services, Health Resources and
Service Administration ($377,123.00, unfunded)

Publications
Nassar, S. L., Berkout, O. V., & Wilson, K. G. (in preparation). Preliminary Psychometric
Properties of the Valued Living Questionnaire–II: An Expanded Measure of Values
and Committed Action.
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Nassar, S. L., Conklin, H. M., Ashford, J. M., Reddick, W. E., Glass, J. O., Jeha, S., Zhou, Y.,
Cheng, C., & Pui, C-H. (in preparation). Cognitive outcomes in children experiencing
seizures during treatment for Acute Lymphoblastic Leukemia.
Gustafson, S. A., Nassar, S. L., & Waddell, D. E. (in preparation). Neurotherapy of neurally
mediated syncope: A single case design. Journal of Neurotherapy.
Bethay, J. S., Wilson, K. G., Schnetzer, L. W., Nassar, S. L., & Bordieri, M. J. (2012). A
controlled pilot evaluation of Acceptance and Commitment Training for intellectual
disability staff. Mindfulness, Online First. doi: 10.1007/s12671-012-0103-8
Wilson, K. G., Flynn, M. K., Bordieri, M., Nassar S. L., Lucas, N. N., & Whiteman. K. C.
(2011). Acceptance and Cognitive Behavior Therapy. In W. O’Donohue & J. E. Fisher
(Eds.) Cognitive Behavior Therapy: Core Principles for Practice. Hoboken, NJ: Wiley.
Waddell, D. E., Nassar, S. L., & Gustafson, S. A. (2011). Single-case design in
psychophysiological research. Part II: Statistical analytic approaches. Journal of
Neurotherapy, 15(2), 160-169.
Gustafson, S. A., Nassar, S. L., & Waddell, D. E. (2011). Single-case design in
psychophysiological research. Part I: Context, structure, and techniques. Journal of
Neurotherapy, 15(1), 18-34.
Nassar, S. L. (2010). A measure of interest to logotherapy researchers: The Death Depression
Scale. The International Forum for Logotherapy, 33(1), 56-57.
Nassar, S. L. (2009). A measure of interest to logotherapy researchers: The Valued Living
Questionnaire. The International Forum for Logotherapy, 32(2), 121-122.
Nassar, S. L. (2009). A measure of interest to logotherapy researchers: The Meaningful Life
Measure. The International Forum for Logotherapy, 32(1), 56-57.
Nassar, S. L. (2008). A measure of interest to logotherapy researchers: The Satisfaction With
Life Scale. The International Forum for Logotherapy, 31(2), 114-115.
Nassar, S. L. (2008). A measure of interest to logotherapy researchers: The Hope Scale. The
International Forum for Logotherapy, 31(1), 55-56.
Nassar, S. L. (2007). Movies of interest to logotherapists. The International Forum for
Logotherapy, 30(2), 112-115.
Nassar, S. L. (2007). A measure of interest to logotherapy researchers: The Humor Styles
Questionnaire. The International Forum for Logotherapy, 30(1), 48-50.
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Nassar, S. L. (2006). A measure of interest to logotherapy researchers: The Love Attitudes Scale.
The International Forum for Logotherapy, 29(2), 119-121.
Schulenberg, S. E., & Nassar, S. L. (2006, April 5). Meaningful cinema: Logotherapy and
Finding Neverland [Review of the motion picture Finding Neverland].
PsycCRITIQUES-Contemporary Psychology: APA Review of Books, 51 (No. 14),
Article 17. Retrieved April 5, 2006, from the PsycCRITIQUES database.

Presentations
Nassar, S. L. (2012, December). Acceptance and Commitment Therapy: An experiential walk
around the Hexaflex. Invited talk presented at Vanderbilt University, Nashville, TN.
Gustafson, S. A., & Nassar, S. L. (2012, October). Time Series Design in Clinical
Neuropsychophysiology. Invited lecture presented at the University of Alabama,
Tuscaloosa, AL.
Nassar, S. L., Wilson, K. G., Kellum. K. K. (2012, July). Defusion as a core ACT process:
Conceptual definitions, current empirical literature, and future directions for
exploration. In H. Bolderston (Chair), Cognitive fusion: Conceptualization and
empirical findings. Symposium presented at the 10th Annual World Conference of the
Association for Contextual Behavioral Science, Washington, D.C.
Nassar, S. L., Conklin, H., M., Ashford, J. M., Zhou, Y., Cheng, C., Reddick, W. E., Glass, J. O.,
Jeha, S., & Pui, C-H. (2012, April). Cognitive Outcomes in Children Experiencing
Seizures during Treatment for Acute Lymphoblastic Leukemia. In K. Tercyak & C. J.
Heckman (Chairs), Pediatric Oncology: Survivorship and Prevention. Paper session
presented at the 33rd Annual Meeting & Scientific Sessions of the Society of
Behavioral Medicine, New Orleans, LA.
Nassar, S. L. & Wilson, K. G. (2011, June). Adapting the Expressive Writing Paradigm as a
Values-Based Intervention. In S. L. Nassar (Chair), New Directions in Values
Assessment and Intervention. Symposium presented at the 9th Annual World
Conference of the Association for Contextual Behavioral Science, Parma, Italy.
Parman, M., Nassar, S. L., Kellum, K. K., & Wilson, K. G. (2011, May). Adapting the
Expressive Writing Paradigm as a Values-Based Intervention. In A. Branstetter-Rost
(Chair), The Potential Utility of Expressive Writing in Acceptance and Commitment
Therapy: Moving Behavior in Valued Directions. Symposium presented at the 37th
Annual Convention for the Association for Behavior Analysis International, Denver,
CO.
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Nassar, S. L., Wilson, K. G., & Kellum, K. K. (2010, June). Update on Values-Centered
Adaption of the Expressive Writing Paradigm. In S. L. Nassar (Chair), Research and
Therapeutic Application in the Context of Valued Living. Symposium presented at the
8th Annual World Conference of the Association for Contextual Behavioral Science,
Reno, NV.
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